General Cancer Surgery
Q 1 – 25
Q1What is a surgical oncologist and how is this different from a general surgeon?
A surgical oncologist dedicates their entire practice to cancer — performing biopsies, tumour resections, lymph node dissections, and reconstructions within a multidisciplinary oncology team. A general surgeon treats a broad mix of benign and malignant conditions. For cancer patients, the surgical oncologist's exclusive focus, high operative volume in specific cancers, and familiarity with evidence-based protocols translate directly into better margins, better staging, and better long-term outcomes. Subspecialty expertise matters most for complex cancers requiring precise dissection, vascular reconstruction, or multi-organ resection.
Q2Is surgery always the first treatment for cancer?
Not always. Many cancers benefit from chemotherapy or radiotherapy before surgery — called neoadjuvant treatment — to shrink the tumour, eliminate micrometastases, and sometimes make an inoperable case resectable. Rectal cancer routinely receives chemoradiation first; gastric cancer receives FLOT chemotherapy; oesophageal cancer receives the CROSS protocol before resection. The correct sequence — surgery first versus chemotherapy first — is decided at MDT review based on the cancer's biology and stage, not by a fixed rule.
Q3What does R0 resection mean and why does it matter so much?
R0 means complete tumour removal with no cancer cells at the cut margins — the most important surgical quality indicator across virtually all solid cancers. R1 means microscopic tumour at the margin; R2 means visible residual tumour left behind. R0 is the single strongest predictor of cure. In rectal cancer, quality TME achieving R0 reduces local recurrence from 30% to under 5%. In pancreatic cancer, R0 resection is the only treatment offering any chance of long-term survival. Every step of a cancer operation — dissection plane, incision, margin measurement — is made to achieve R0.
Q4What is neoadjuvant treatment and when is it given before surgery?
Neoadjuvant treatment — chemotherapy, radiotherapy, or both — given before surgery achieves three goals: shrinks the primary tumour enabling resection or organ preservation; treats micrometastatic disease imaging cannot detect; and tests tumour biology — a tumour progressing through chemotherapy has aggressive characteristics that influence the surgical plan. Standard uses include: FLOT for gastric cancer, CROSS for oesophageal cancer, combined chemoradiation for rectal cancer, and anthracycline-taxane for breast cancer. Response to neoadjuvant treatment directly guides decisions on adjuvant treatment after surgery.
Q5What is an MDT and why does every cancer patient need one?
MDT — Multidisciplinary Team — is a structured meeting where surgical oncologist, medical oncologist, radiation oncologist, radiologist, and pathologist review every cancer patient together before treatment begins. No single specialist's view dominates; plans reflect collective expertise against evidence-based guidelines. Studies consistently show MDT-reviewed patients have higher guideline-concordant treatment rates, fewer unnecessary operations, and better survival compared to single-specialist management. At Sahyadri Manipal Hospital Pune, Dr. Gore presents every new cancer case at MDT before recommending any treatment plan.
Q6What is sentinel lymph node biopsy?
Sentinel node biopsy identifies the first lymph node draining a tumour — using blue dye, radioactive tracer, or ICG fluorescence. Only that node is removed and examined. If it is cancer-free, the remaining 15–20 regional nodes are almost certainly clear, and full lymph node dissection — with its risks of lymphoedema, nerve damage, and prolonged surgery — is safely avoided. Sentinel node biopsy has transformed breast cancer, melanoma, and gynaecological cancer surgery, dramatically reducing operative morbidity while maintaining oncological accuracy. Dr. Gore uses ICG fluorescence for sentinel node identification across multiple cancer types.
Q7What does inoperable cancer mean — and can this change?
Inoperable means surgery cannot safely achieve clear margins at this point — usually because the tumour has grown around major blood vessels or into adjacent organs making complete resection impossible. This assessment must be made by an experienced surgical oncologist reviewing the actual imaging, not just the radiology report. Neoadjuvant chemotherapy converts 15–25% of initially unresectable tumours to resectable. Many patients labelled inoperable at general hospitals are successfully operated at specialist cancer surgery centres. A second opinion before accepting an inoperable diagnosis is essential — call 88558 10010.
Q8What is palliative surgery in cancer?
Palliative surgery relieves symptoms — obstruction, pain, bleeding, perforation — without curing the cancer. Examples: defunctioning colostomy for bowel obstruction; biliary bypass for jaundice from unresectable pancreatic cancer; gastric bypass for outlet obstruction; spinal stabilisation for vertebral metastases. Palliative surgery is not lesser surgery — it requires the same careful MDT review, patient selection, and surgical judgement as curative operations. The goal is meaningful, durable quality-of-life improvement with acceptable operative risk. Dr. Gore's team provides palliative surgical options for advanced cancer patients at Sahyadri Manipal Hospital Pune.
Q9What is PET-CT and when is it needed before cancer surgery?
PET-CT combines metabolic imaging (FDG-PET detecting cancer's high glucose uptake) with precise anatomical localisation (CT). It identifies distant metastases, lymph node spread, and peritoneal deposits that standard CT or MRI may miss — changing the surgical plan in 20–30% of cases for gastric, oesophageal, and colorectal cancers. PET-CT is essential before major cancer resections to confirm absence of systemic spread that would change intent from curative to palliative. It is now routine in preoperative staging at specialist cancer centres including Sahyadri Manipal Hospital Pune.
Q10What is surgical staging laparoscopy and when is it used?
Staging laparoscopy is a brief keyhole procedure under general anaesthesia allowing inspection of the peritoneal cavity, liver surface, and lymph nodes before committing to major resection. Most valuable for gastric cancer — detecting peritoneal deposits in 15–30% of patients deemed resectable on CT, sparing them an unnecessary laparotomy. Also used for pancreatic cancer, ovarian cancer, and oesophagogastric junction tumours. Peritoneal washing cytology collected simultaneously — positive cytology upstages the patient to Stage IV, changing management from curative surgery to systemic chemotherapy. A 30–45 minute procedure with disproportionately high clinical value.
Q11What is immunohistochemistry (IHC) and why is it done on every biopsy?
IHC stains biopsy tissue with specific antibodies to identify cancer subtype, receptor status, and molecular markers — essential for treatment planning. In breast cancer, IHC determines ER, PR, and HER2 status guiding hormone therapy and trastuzumab decisions. In colorectal cancer, mismatch repair IHC identifies MSI-high tumours eligible for immunotherapy. In GIST, CD117 (KIT) staining confirms diagnosis and predicts imatinib response. Modern cancer surgery is driven by molecular pathology — an adequate biopsy with full IHC panel is the mandatory first step for every cancer patient before any treatment decision is made.
Q12What is adjuvant chemotherapy after cancer surgery?
Adjuvant chemotherapy is systemic treatment given after surgery — targeting microscopic cancer cells that may have spread to distant sites beyond what imaging can detect. It starts 4–6 weeks post-operatively once the wound is healed. Standard regimens: FOLFOX or CAPOX for Stage III colorectal cancer reducing recurrence by 30%; FLOT for gastric cancer; carboplatin-paclitaxel for high-risk endometrial cancer. The decision is made at oncology MDT after pathological review of the surgical specimen — stage, nodal status, grade, and molecular markers all inform the recommendation.
Q13Does cancer surgery spread cancer to other parts of the body?
No — correctly performed cancer surgery does not cause cancer to spread. Surgical dissection follows defined anatomical planes outside the tumour envelope; the no-touch technique minimises direct tumour handling; specimens are removed intact. The theoretical risk of tumour cell seeding has been extensively studied and found clinically insignificant with correct oncological technique. The genuine risk is an incomplete resection with positive margins — which is why subspecialty surgical oncology expertise and high operative volume are the most important factors in protecting patients from recurrence after surgery.
Q14What is ERAS — Enhanced Recovery After Surgery?
ERAS is a multimodal evidence-based programme replacing outdated practices: carbohydrate loading the night before surgery instead of prolonged fasting; early oral feeding within 24–48 hours post-operatively; mobilisation within hours of surgery; multimodal non-opioid analgesia; and avoidance of unnecessary drains and catheters. Clinical trials show ERAS reduces hospital stay by 30–40% and complications by 20–30% without increasing readmission. Dr. Gore's team follows ERAS principles for all major colorectal, HPB, and thoracic cancer operations at Sahyadri Manipal Hospital — most patients walk within 24 hours and eat within 48 hours.
Q15How should I prepare for major cancer surgery?
Preparation covers four domains. Physical: stop smoking 4–6 weeks before surgery; optimise diabetes (HbA1c below 8%), hypertension, and cardiac conditions. Nutritional: high-protein diet and oral supplements to correct malnutrition; immunonutrition for 5–7 days pre-operatively. Functional: walking 30 minutes daily, breathing exercises, and physiotherapy — prehabilitation speeds post-operative recovery. Psychological: understand the procedure, expected timeline, stoma care if applicable, and available support. Dr. Gore's team provides a personalised pre-operative preparation plan including dietitian review and stoma nurse counselling where applicable.
Q16What is a tumour marker blood test and how reliable is it?
Tumour markers are proteins produced by cancer cells measurable in blood — CEA (colorectal), CA 19-9 (pancreatic and biliary), CA-125 (ovarian), AFP (liver and germ cell), PSA (prostate). Most valuable for monitoring treatment response and detecting recurrence after treatment. For primary diagnosis alone they are unreliable — most markers can be elevated by benign conditions including liver disease, pancreatitis, and endometriosis. A rising tumour marker must always be interpreted alongside imaging and clinical assessment by an experienced oncologist, never in isolation.
Q17What is ICG fluorescence surgery and how does it help cancer patients?
ICG (Indocyanine Green) fluorescence is integrated into the da Vinci Xi robotic camera — illuminating tissue under near-infrared light in real time during surgery. Dr. Gore uses ICG routinely for: confirming blood supply to bowel anastomoses before completion, reducing anastomotic leak from 12% to 1.4% (PILLAR III trial); detecting hidden liver metastases not visible on CT or MRI (found in 15–25% of CRLM operations); mapping liver segment boundaries; and identifying bile duct anatomy to prevent injury. ICG fluorescence is standard in all major robotic cancer operations at Sahyadri Manipal Hospital Pune.
Q18What is lymph node dissection in cancer surgery?
Lymph node dissection removes regional nodes draining the tumour — for staging and disease control. Pathological node examination determines N-status — the strongest predictor of recurrence risk in most cancers and the primary driver of the adjuvant chemotherapy decision. Lymph node yield is a key surgical quality metric: minimum 12 nodes for colorectal cancer, 16 nodes for gastric cancer. Inadequate harvest causes understaging and missed opportunities for adjuvant treatment that can reduce recurrence risk by 30%. Robotic surgery achieves equivalent or superior nodal yield to open surgery across colorectal, gastric, and gynaecological cancers.
Q19What does cancer Stage 4 mean and can surgery still help?
Stage 4 means cancer has spread to distant organs — but it does not automatically exclude surgery and can sometimes still mean cure. Colorectal cancer with liver or lung metastases: hepatectomy or pulmonary metastasectomy achieves 30–50% five-year survival. Selected Stage 4 neuroendocrine tumours, adrenal metastases from renal cell cancer, and solitary sarcoma deposits are all operated with curative intent. The critical question is not the stage label alone but the biology and anatomical distribution of the metastatic disease. An experienced surgical oncologist must review all imaging before concluding Stage 4 is beyond surgical treatment.
Q20What is TNM staging in cancer?
TNM classifies cancer by three dimensions: T (Tumour) describing the size and local extent of the primary tumour on a scale of T1–T4; N (Nodes) describing regional lymph node involvement on a scale of N0–N3; and M (Metastasis) describing the presence or absence of distant spread as M0 or M1. These combine to give an overall Stage I through IV. Stage I is localised and highly curable with surgery. Stage IV has distant spread — surgery may still be curative in selected situations but often requires systemic therapy first or instead.
Q21What is cancer screening and who needs it in India?
Screening detects cancer before symptoms develop — at its most curable stage. Evidence-based programmes: colonoscopy every 10 years from age 45 for colorectal cancer; annual mammography from age 40–50 for breast cancer; Pap smear or HPV co-testing every 3–5 years for cervical cancer; low-dose CT for high-risk smokers for lung cancer. High-risk individuals — BRCA carriers, Lynch syndrome, strong family history — need earlier and more frequent screening. Silver Leaf Clinic, Hadapsar, Pune provides cancer risk assessment and personalised screening recommendations. Call 88558 10010 to book a cancer screening consultation.
Q22When should I get a second opinion before cancer surgery?
A second opinion is strongly recommended when: told the cancer is inoperable; surgery involves organ removal or permanent stoma; the cancer is rare (GIST, NET, sarcoma); you have received conflicting recommendations; or you simply want reassurance before a major operation. Getting a second opinion does not delay treatment meaningfully and does not offend your treating doctor. Dr. Gore welcomes second opinion consultations at Silver Leaf Clinic, Hadapsar. Bring all imaging on CD or WhatsApp, biopsy reports, and any treatment summaries. Call 88558 10010 or WhatsApp 84118 08284.
Q23What are the risks of major cancer surgery?
All major surgery carries risks — bleeding, wound infection, anaesthetic complications, DVT, and pulmonary embolism. Procedure-specific risks include anastomotic leak after bowel surgery, pancreatic fistula after Whipple surgery, and recurrent laryngeal nerve injury after thyroidectomy. All relevant risks are discussed in detail at the pre-operative consultation. These risks must always be weighed against the risk of not operating — for resectable cancer, leaving the tumour untreated is invariably more dangerous than surgery at a specialist centre with high operative volume and dedicated oncological expertise.
Q24What is oncoplastic surgery?
Oncoplastic surgery combines cancer removal with simultaneous plastic reconstruction — achieving cancer clearance without compromising form or function. In breast cancer, it removes the tumour with wide margins while using volume-displacement or volume-replacement techniques to preserve breast shape. In head and neck cancer, flaps restore speech and swallowing after oral resection. In rectal cancer, VRAM flaps reconstruct the perineum after APR. Dr. Gore completed three years of plastic and reconstructive surgery training at Sassoon General Hospital Pune — these skills are integrated throughout his comprehensive oncosurgical practice.
Q25What is the role of MDT in cancer surgery decision-making?
MDT — Multidisciplinary Team — review prevents any single specialist's opinion from dominating treatment decisions. The surgical oncologist, medical oncologist, radiation oncologist, radiologist, and pathologist together reach a consensus plan that reflects all treatment options and the latest evidence. MDT review is now mandatory at all accredited cancer centres internationally. For patients, it means no treatable cancer is dismissed as inoperable without multiple specialists agreeing, no surgery is recommended when chemotherapy should come first, and no adjuvant treatment is missed after surgery. Every patient managed by Dr. Gore is presented at MDT at Sahyadri Manipal Hospital before treatment begins.
Robotic Cancer Surgery
Q 26 – 45
Q26What is robotic cancer surgery and how does it work?
Robotic surgery uses the da Vinci Xi system — four robotic arms with miniaturised instruments and a 3D high-definition camera — inserted through 8–12mm port incisions. The surgeon operates from a console, viewing a 10x magnified three-dimensional image and translating hand movements into precise, tremor-filtered actions inside the patient. The system has no autonomy — it responds entirely to the surgeon. The result: complex cancer operations through minimal incisions with equivalent or superior oncological accuracy to open surgery, dramatically less pain, and significantly faster recovery. Dr. Gore leads the robotic cancer programme at Sahyadri Manipal Hospital, Pune.
Q27What is FARIS and why does it matter when choosing a robotic surgeon?
FARIS — Fellowship in Advanced Robotic and Innovative Surgery — from the University of Edinburgh is one of the highest robotic surgery credentials globally, held by very few surgeons in India. It requires demonstrated advanced proficiency in robotic technique, teaching, and programme development across multiple organ systems. Dr. Gore is a FARIS holder and an accredited FARIS training mentor — meaning he certifies other robotic surgeons. The Robotic Cancer Surgery Centre of Excellence at Sahyadri Manipal Hospital Pune is ARIS-accredited. When choosing a robotic cancer surgeon, FARIS certification, procedure volume, and centre accreditation are the most important credentials to verify.
Q28What are the main advantages of robotic over open surgery for cancer?
Robotic surgery provides 60–80% less blood loss than equivalent open procedures; port incisions of 8–12mm versus open wounds of 20–30cm; lower wound infection and hernia rates; substantially less post-operative pain enabling earlier mobilisation; hospital stay of 3–5 days versus 7–14 days; and faster return to work and normal activities. Oncological outcomes — R0 resection rates, lymph node yield, and long-term survival — are equivalent to open surgery across all major trials. For cancer in confined spaces like the narrow pelvis or mediastinum, the robotic system offers meaningful technical advantages over both open and standard laparoscopic approaches.
Q29What cancers are best treated with robotic surgery?
Robotic surgery benefits most the cancers in confined anatomical spaces where 3D magnification and instrument dexterity provide clear clinical advantages: rectal cancer — TME in the narrow pelvis with nerve-sparing and sphincter preservation; gastric cancer — D2 lymphadenectomy in the suprapancreatic region; oesophageal cancer — RAMIE, the two-phase thoracoscopic and abdominal approach; pancreatic cancer — Whipple and distal pancreatectomy; gynaecological cancers — radical hysterectomy and pelvic lymphadenectomy; urological cancers — prostatectomy, nephrectomy, cystectomy; and thoracic cancer — lobectomy and oesophagectomy. Dr. Gore performs robotic surgery across all these cancer types at Sahyadri Manipal Hospital Pune.
Q30Is robotic cancer surgery as effective as open surgery for cancer cure?
Yes. Multiple large randomised trials confirm robotic cancer surgery achieves equivalent oncological outcomes to open surgery — equivalent R0 resection rates, lymph node yield, margin status, and long-term survival across colorectal, gastric, prostate, kidney, endometrial, and thoracic cancers. The ROLARR trial for rectal cancer, COLOR II for colon cancer, and multiple RCTs for prostatectomy all confirm this equivalence. The benefits of robotic surgery lie in recovery and functional outcomes — not in any compromise to cancer cure. Patients achieve the same cure rates as open surgery with a significantly lower physiological cost to the body.
Q31What is robotic TME surgery for rectal cancer?
Robotic Total Mesorectal Excision is the preferred approach for rectal cancer requiring resection. The rectum and its surrounding mesorectal envelope — containing blood vessels, lymph nodes, and critical autonomic nerve bundles — are sharply dissected under 10x 3D vision in the narrow pelvis. This precision preserves the nerves responsible for bladder and sexual function while achieving the clear circumferential margin that prevents local recurrence. Quality robotic TME reduces local recurrence from 25–30% to under 5%. The ROLARR trial confirmed robotic TME has significantly lower conversion rates and better functional outcomes than laparoscopic or open TME, particularly in male patients.
Q32Can robotic surgery preserve sexual and bladder function after rectal cancer?
Yes — this is robotic surgery's most important advantage in rectal cancer. The autonomic nerves controlling bladder and sexual function run within millimetres of the surgical dissection plane in the pelvis. The 10x magnified 3D view allows precise identification and protection of these nerve bundles with accuracy not achievable in open or laparoscopic surgery. The REAL trial confirmed robotic TME achieves significantly better preservation of urinary and sexual function. For younger patients and those prioritising quality of life, this functional advantage is as clinically important as the oncological outcome — both are achieved simultaneously with robotic rectal cancer surgery.
Q33What is robotic Whipple surgery for pancreatic cancer?
Robotic pancreaticoduodenectomy removes the pancreatic head, duodenum, bile duct, gallbladder, and often the distal stomach through 5–6 small port incisions. The 10x magnified 3D view during dissection of the superior mesenteric vessels — the oncologically critical step — and during construction of the three anastomoses (pancreatic, biliary, and gastric) provides precision not achievable in open surgery. Robotic Whipple achieves equivalent R0 resection and nodal yield to open surgery with significantly less blood loss and shorter hospital stay, allowing earlier commencement of adjuvant chemotherapy. Dr. Gore performs robotic Whipple at Sahyadri Manipal Hospital, Pune.
Q34What is RAMIE — Robotic Assisted Minimally Invasive Esophagectomy?
RAMIE is a two-phase operation for oesophageal cancer — robotic thoracoscopic dissection of the oesophagus and mediastinal lymph nodes, followed by robotic abdominal mobilisation of the stomach and formation of a gastric conduit. ICG fluorescence confirms blood supply to the conduit tip before anastomosis — preventing conduit ischaemia, the most feared complication. RAMIE achieves lower pulmonary complication rates and shorter ICU stay than open thoracotomy. Dr. Gore has a dedicated research interest in thoracic oncology from his Fellowship at Tata Memorial Hospital. RAMIE is his preferred approach for oesophageal cancer at Sahyadri Manipal Hospital Pune.
Q35What is robotic gastrectomy for stomach cancer?
Robotic gastrectomy removes all or part of the stomach for gastric cancer — distal or total gastrectomy — with a complete D2 lymph node dissection. D2 lymphadenectomy is the international quality standard for gastric cancer surgery; the suprapancreatic nodal dissection is technically demanding and significantly facilitated by robotic 3D magnification. Robotic gastrectomy achieves equivalent D2 nodal clearance to open surgery with significantly less blood loss, lower wound complication rate, and faster recovery. Reconstruction — Billroth II or Roux-en-Y — is completed robotically in the same session. FLOT neoadjuvant chemotherapy is given before surgery for Stage II–III gastric cancer.
Q36Is robotic cancer surgery safe for elderly patients?
Robotic surgery is frequently preferred for elderly patients precisely because it is less physiologically traumatic than open surgery. Smaller incisions, better haemostasis, less post-operative pain, earlier mobilisation, and shorter hospital stay are the characteristics that most benefit older patients with reduced cardiac and pulmonary reserve. Fitness for surgery is assessed by functional status, organ reserve, and performance score — not chronological age alone. Many patients in their 70s and 80s safely undergo complex robotic cancer operations at Sahyadri Manipal Hospital Pune, with outcomes comparable to younger patients with equivalent performance status. Age alone is never a contraindication to robotic cancer surgery.
Q37What is robotic surgery for gynaecological cancers?
Robotic surgery is the preferred minimally invasive platform for gynaecological cancer — radical hysterectomy for cervical cancer, total hysterectomy with pelvic lymphadenectomy for endometrial cancer, and staging procedures for early ovarian cancer. Compared to open surgery: less blood loss, hospital stay 1–3 days versus 5–7 days, faster recovery. Compared to standard laparoscopy: 3D magnification and wristed instruments enable safer parametrial resection, more precise lymphadenectomy, and better vaginal cuff closure. The LACC trial technical modifications — no uterine manipulator, colpotomy bag — used in Dr. Gore's programme ensure oncological equivalence to open surgery.
Q38What is ICG fluorescence in robotic cancer surgery?
ICG — Indocyanine Green — fluorescence is integrated into the da Vinci Xi's FireFly camera, providing real-time near-infrared imaging without changing instruments during robotic surgery. Dr. Gore uses ICG routinely for: anastomotic perfusion assessment before completing bowel joins, reducing leak rate from 12% to 1.4% (PILLAR III trial); detecting occult liver metastases not seen on CT or MRI in 15–25% of CRLM operations; mapping liver segment boundaries for precise anatomical resection; bile duct anatomy identification; and gastric conduit perfusion in oesophagectomy. ICG is a standard component of all major robotic cancer operations at Sahyadri Manipal Hospital Pune.
Q39What is the difference between robotic and laparoscopic surgery?
Both are minimally invasive but robotic surgery offers critical technical advantages for complex cancer operations. Standard laparoscopy: 2D flat screen image, straight instruments with limited range of motion, hand tremor transmitted to instrument tip. Robotic: fully immersive 3D magnified view at 10x, instruments with 7 degrees of freedom including wristed motion replicating the human wrist, and complete tremor filtration by the computer. These differences matter most during complex cancer dissections in confined spaces — pelvic TME, mediastinal oesophagectomy, and vascular surgery in Whipple's — where robotic precision translates into measurably better surgical outcomes.
Q40Which hospital has robotic cancer surgery in Pune?
Sahyadri Manipal Hospital, Hadapsar, Pune is the designated Robotic Cancer Surgery Centre of Excellence — ARIS accredited — led by Dr. Vinod T. Gore. The programme operates the da Vinci Xi platform for the full range of GI, HPB, thoracic, urological, and gynaecological cancer operations. It is also an accredited FARIS training centre where Dr. Gore trains and certifies other robotic surgeons. Consultations at Silver Leaf Clinic, 511 City Centre, Solapur Road, Hadapsar, Pune 411028. Call 88558 10010. Full robotic surgery programme details at bestroboticsurgeonpune.in.
Q41How long is recovery after robotic cancer surgery?
Recovery is substantially faster than after open surgery. Robotic colectomy: hospital 3–5 days, office work at 2–3 weeks. Robotic gastrectomy: hospital 5–7 days, full recovery 4–6 weeks. Robotic Whipple: hospital 7–10 days, full recovery 6–8 weeks. Robotic oesophagectomy: hospital 8–12 days, full recovery 6–8 weeks. These compare to 8–12 weeks recovery for equivalent open procedures. ERAS protocols at Sahyadri Manipal Hospital — early feeding, early mobilisation, multimodal analgesia — accelerate all timelines further. Most patients are walking within 24 hours and eating within 48 hours after major robotic cancer surgery.
Q42What is robotic prostatectomy?
Robotic radical prostatectomy removes the prostate and seminal vesicles for localised prostate cancer — with bilateral nerve-sparing technique preserving the neurovascular bundles responsible for erectile function. The 10x 3D view enables precise identification of nerves and the urethral sphincter controlling continence. Bilateral nerve-sparing RARP achieves continence recovery in 85–95% and erectile function recovery in 60–80% of appropriately selected younger patients. Pelvic lymph node dissection is performed for intermediate and high-risk disease. Post-operative PSA should be undetectable at 6 weeks. Full robotic programme including prostatectomy details at bestroboticsurgeonpune.in.
Q43What is the da Vinci Xi system?
The da Vinci Xi is the latest generation surgical robot from Intuitive Surgical. Key features: fully re-architected arms rotating 360 degrees enabling multi-quadrant surgery without re-docking; boom-mounted design for faster setup; integrated FireFly near-infrared fluorescence camera for real-time ICG imaging without instrument changes; the most advanced energy instruments including Vessel Sealer Extend; and robotic stapler for intracorporeal anastomoses. The Xi enables complex multi-quadrant GI cancer operations without repositioning. Sahyadri Manipal Hospital, Hadapsar, Pune operates the da Vinci Xi platform — the gold standard for robotic cancer surgery worldwide.
Q44What is the cost of robotic cancer surgery in Pune?
Approximate costs at Sahyadri Manipal Hospital Pune: robotic colectomy Rs 2.5–4 lakhs; robotic anterior resection Rs 3–5 lakhs; robotic gastrectomy Rs 3.5–5.5 lakhs; robotic Whipple Rs 5–8 lakhs; robotic oesophagectomy Rs 5–8 lakhs; robotic hysterectomy Rs 2.5–4 lakhs; robotic prostatectomy Rs 2.5–4 lakhs; robotic nephrectomy Rs 2.5–3.5 lakhs. These include surgery, anaesthesia, robotic consumables, ICU, ward, and standard medications. Pre-operative investigations and adjuvant chemotherapy are additional. Cashless insurance accepted from most major TPA networks. MJPJAY government scheme available for eligible patients. Detailed estimate provided by hospital billing before admission.
Q45Robotic surgery kya hai aur kya yeh cancer ke liye safe hai? (Hindi)
Robotic surgery mein surgeon ek console se robotic arms ko control karta hai jo patient ke andar chhote 8–12mm chhedon se kaam karte hain. Surgeon ko 3D high-definition screen pe 10x magnified nazar aata hai — khuli surgery ke barabar cancer removal ke saath. Robotic surgery cancer ke liye bilkul safe hai — duniya bhar mein lakho cancer patients ka safal ilaj is technique se hua hai. Fayde: kam khoon, chhota dard, jaldi recovery, chhoti wounds. Sahyadri Manipal Hospital Hadapsar Pune mein Dr. Vinod Gore — FARIS Edinburgh, 300+ robotic procedures — robotic cancer surgery ka programme chalate hain. Appointment ke liye call karein: 88558 10010.
Breast Cancer Surgery
Q 46 – 65
Q46What is the difference between lumpectomy and mastectomy?
Lumpectomy removes the tumour with a surrounding margin of normal tissue — preserving the breast — followed by radiotherapy to eliminate residual microscopic disease. Long-term survival after lumpectomy plus radiotherapy is equivalent to mastectomy for early breast cancer. Mastectomy removes the entire breast — indicated when the tumour is large relative to breast size, when cancer is multifocal, in BRCA mutation carriers, when radiotherapy is contraindicated, or by patient choice. Oncoplastic techniques extend conservation to larger tumours using tissue redistribution. The decision is made jointly by patient and surgeon based on tumour characteristics, breast size, genetic risk, and patient preference.
Q47What is oncoplastic breast surgery and when is it recommended?
Oncoplastic surgery combines cancer excision with simultaneous breast reshaping — removing the tumour with adequate oncological margins while redistributing remaining breast tissue to fill the defect and preserve shape. Volume displacement techniques redistribute existing tissue; volume replacement techniques use adjacent tissue (miniflaps) for larger defects. Contralateral symmetrisation is often performed in the same session. Oncoplastic surgery is recommended when standard lumpectomy would leave a significant cosmetic defect, or when the tumour is too large for standard conservation but the patient wishes to avoid mastectomy. Studies confirm equivalent margin clearance and local recurrence rates to standard lumpectomy.
Q48What is sentinel node biopsy in breast cancer?
Sentinel node biopsy identifies the first axillary lymph node draining the breast tumour using blue dye, radioactive tracer, or ICG fluorescence, and removes only that node for examination. If it is cancer-free, full axillary clearance — removal of 15–20 nodes — is safely avoided, eliminating the risk of arm lymphoedema in most node-negative patients. The false-negative rate is under 5% in experienced hands. Sentinel node biopsy is the standard for clinically node-negative breast cancer — one of the most impactful advances in breast cancer surgical practice, dramatically reducing morbidity without compromising oncological accuracy.
Q49What is nipple-sparing mastectomy?
Nipple-sparing mastectomy removes all breast glandular tissue through a periareolar or inframammary incision while preserving the nipple-areola complex and skin — allowing the best aesthetic outcome for immediate implant or flap reconstruction. NSM is suitable when the tumour is peripheral and not immediately behind the nipple, the nipple biopsy shows no cancer involvement, and there are no nipple or skin changes on examination. For BRCA carriers choosing prophylactic mastectomy, NSM combined with immediate reconstruction is an excellent option. Long-term oncological outcomes are equivalent to conventional mastectomy when correct patient selection criteria are applied.
Q50What are the breast reconstruction options after mastectomy?
Reconstruction options: implant-based — silicone implant, often preceded by a tissue expander placed at mastectomy; LD flap — skin and muscle from the back, reliable and widely used; DIEP flap — skin and fat from the lower abdomen without using the muscle, providing the most natural result and feel without abdominal weakness; TRAM flap — similar to DIEP but using the rectus abdominis muscle. Choice depends on body habitus, whether radiotherapy is planned (implants have higher complication rates in irradiated fields), patient preference, and surgical expertise. Nipple reconstruction and tattooing complete the process. Dr. Gore's plastic surgery training enables all reconstruction options.
Q51What is HER2 positive breast cancer?
HER2-positive breast cancer overexpresses the HER2 growth factor receptor — making tumours more aggressive but highly responsive to anti-HER2 targeted therapy. HER2 status is confirmed by IHC staining (3+ positive) with FISH confirmation for equivocal cases. Treatment: neoadjuvant trastuzumab + pertuzumab + chemotherapy achieves pathological complete response in 40–70% of patients. Achieving pCR — no cancer in the surgical specimen — is one of the most powerful prognostic markers in breast cancer. Surgery follows standard lumpectomy or mastectomy principles after neoadjuvant treatment, with the extent determined by response to systemic therapy.
Q52What is triple-negative breast cancer?
Triple-negative breast cancer (TNBC) lacks oestrogen receptor, progesterone receptor, and HER2 expression — making it unresponsive to hormone therapy and trastuzumab. It accounts for 15–20% of breast cancers, occurs at younger ages, is more common in BRCA1 carriers, and is typically aggressive. Neoadjuvant chemotherapy is the standard first step — the KEYNOTE-522 regimen (pembrolizumab + chemotherapy) achieves pCR in 50–60%. Surgery follows neoadjuvant treatment: lumpectomy or mastectomy based on response and tumour characteristics. Patients not achieving pCR receive adjuvant Capecitabine. BRCA testing is recommended for all TNBC patients.
Q53What is BRCA gene testing and who needs it?
BRCA1 and BRCA2 mutations carry lifetime breast cancer risks of 60–80% and elevated ovarian cancer risks of 40–60%. Genetic testing is strongly recommended for: breast cancer diagnosed before age 45; triple-negative breast cancer; bilateral breast cancer; male breast cancer; strong family history of breast, ovarian, or pancreatic cancer; and Ashkenazi Jewish ancestry. A positive BRCA result has profound implications — enabling prophylactic surgery or intensified surveillance for the patient and their family members, who carry a 50% risk of inheriting the same mutation. Dr. Gore arranges genetic counselling and testing coordination for all relevant patients.
Q54Can breast cancer be completely cured?
Yes. Early-stage breast cancer is curable in the majority of patients with modern multimodal treatment. Stage I: 5-year survival 90–99%. Stage II: 80–90%. Stage III: 55–75%. Even Stage IV HER2-positive breast cancer — while rarely cured — is increasingly managed as a chronic disease with median survival exceeding 5 years on modern anti-HER2 therapy. The most powerful factors determining cure are stage at diagnosis and tumour biology (ER, PR, HER2 status, Ki-67). Early detection through mammographic screening is the single most impactful intervention — diagnosing cancer at Stage I rather than Stage III dramatically improves the probability of cure.
Q55What are the signs and symptoms of breast cancer?
Signs requiring prompt assessment: a painless breast lump or thickening; skin dimpling or puckering; nipple retraction or inversion; nipple discharge particularly if bloody or unilateral; breast skin redness, warmth, or thickening (inflammatory breast cancer); axillary lymph node swelling; and unexplained change in breast shape or size. Any of these signs must be assessed with breast ultrasound and mammography regardless of age. Early breast cancer is frequently asymptomatic — detected only by mammographic screening. Never attribute a breast lump to fibroadenoma or benign cyst without imaging and biopsy confirmation where indicated.
Q56What is lymphoedema after breast cancer surgery?
Lymphoedema — chronic arm swelling — occurs when axillary lymph node removal disrupts drainage from the arm. Risk: 15–20% after full axillary clearance; under 5% after sentinel node biopsy alone. Management: compression garments, complex decongestive physiotherapy (CDP), and gentle supervised exercise. Prevention: use sentinel node biopsy where possible; avoid blood pressure measurement and cannulation in the affected arm; protect against cuts and infections; maintain healthy body weight. Surgical treatment — lymphovenous anastomosis — is available for severe refractory lymphoedema. The shift to selective sentinel node biopsy has dramatically reduced lymphoedema rates in breast cancer patients over the last 20 years.
Q57What is DCIS (Ductal Carcinoma In Situ) and does it need surgery?
DCIS is cancer confined within the milk ducts — not yet invading surrounding tissue. It cannot spread to lymph nodes in its pure form. However, 30–50% of untreated DCIS will progress to invasive cancer over 10–20 years — making treatment standard. Surgery: lumpectomy with clear margins followed by radiotherapy for most cases; mastectomy for extensive high-grade DCIS. Sentinel node biopsy is performed if mastectomy is planned or invasive component is suspected. Hormone therapy (tamoxifen or aromatase inhibitor) reduces local recurrence after surgery. Active surveillance without surgery remains investigational — not current standard of care outside clinical trials.
Q58What is inflammatory breast cancer?
Inflammatory breast cancer is a rare, aggressive subtype — presenting as rapid diffuse redness, warmth, swelling, and skin thickening of the entire breast, caused by tumour emboli blocking dermal lymphatics. There is often no distinct palpable lump. IBC is Stage IIIB by definition regardless of nodal status. Treatment sequence: neoadjuvant chemotherapy — with anti-HER2 therapy if HER2 positive — always comes first; surgery (modified radical mastectomy) follows; post-mastectomy radiotherapy is mandatory. Lumpectomy is not appropriate for IBC due to diffuse skin involvement. IBC requires immediate specialist oncology MDT assessment from the first consultation.
Q59What is a mammogram and when should I start having one?
A mammogram is an X-ray of the breast detecting microcalcifications, masses, and architectural distortions 2–3 years before they become palpable. Standard recommendation: annual mammography from age 40–50 for average-risk women. High-risk women — BRCA carriers, strong family history — should start from age 30 or 10 years before the youngest affected relative. Mammography reduces breast cancer mortality by 15–20% in screened populations. In India, many women present with advanced disease preventable by earlier detection. Silver Leaf Clinic Hadapsar provides cancer risk assessment and personalised screening recommendations. Call 88558 10010 to book a breast cancer screening consultation.
Q60Who is the best breast cancer surgeon in Pune?
Dr. Vinod T. Gore — 30+ years surgical oncology, Tata Memorial Hospital trained, three years plastic and reconstructive surgery at Sassoon General Hospital Pune, FAIS certified. His oncoplastic breast surgery programme at Sahyadri Manipal Hospital integrates cancer removal with breast shape preservation — lumpectomy, oncoplastic conservation, mastectomy, sentinel node biopsy, and all reconstruction options. Full breast cancer surgery programme at bestbreastsurgeon.in. For consultations at Silver Leaf Clinic, Hadapsar: call 88558 10010 or WhatsApp 84118 08284. Bring mammogram, ultrasound, biopsy report with IHC (ER, PR, HER2, Ki-67) to your first appointment.
Q61What happens if breast cancer has spread to lymph nodes?
Nodal involvement is the most important prognostic factor in early breast cancer — significantly increasing recurrence risk. Treatment implications: neoadjuvant chemotherapy is the standard first step for most node-positive cases; axillary clearance is performed after neoadjuvant treatment; adjuvant chemotherapy is strongly indicated; and post-mastectomy radiotherapy is standard when four or more nodes are positive. With modern systemic therapy, the survival difference between N1 (1–3 nodes positive) and N0 node-negative disease has narrowed considerably — many N1 patients achieve long-term cure with appropriate multimodal treatment at a specialist breast cancer centre.
Q62What is hormone receptor positive breast cancer?
Hormone receptor positive (HR+) breast cancer — expressing oestrogen (ER) and/or progesterone (PR) receptors — accounts for 70% of all breast cancers and depends on oestrogen for growth. It is highly responsive to hormone-blocking therapy: tamoxifen (pre-menopausal), aromatase inhibitors letrozole or anastrozole (post-menopausal), and CDK4/6 inhibitors palbociclib or ribociclib. Surgery follows standard lumpectomy or mastectomy principles. Hormone therapy is given for 5–10 years after surgery. The Oncotype DX genomic assay provides additional information for HR+ HER2-negative node-negative patients — identifying who needs chemotherapy added to hormone therapy, enabling truly personalised treatment.
Q63What is male breast cancer?
Male breast cancer is rare — 1% of all breast cancers — but requires identical oncological rigour. Most are treated with mastectomy rather than breast-conserving surgery due to less breast tissue. Sentinel node biopsy is standard. Most male breast cancers are ER-positive — tamoxifen for 5–10 years is standard adjuvant hormonal therapy. BRCA2 mutations occur in 10% of male breast cancer patients — genetic testing is recommended for all men diagnosed. Any palpable lump or skin change in the male breast must be promptly assessed — stigma frequently causes dangerous diagnostic delays in men with breast cancer, leading to unnecessarily advanced disease at diagnosis.
Q64What is the recovery after mastectomy and breast reconstruction?
Mastectomy alone: hospital 2–4 days, drain removal at 5–10 days, return to light activities 3–4 weeks. Immediate implant reconstruction: hospital 3–5 days, gradual expander filling over 4–8 weeks, full recovery 6–8 weeks. DIEP flap reconstruction: hospital 5–7 days, two healing sites (breast and abdomen), full recovery 8–10 weeks. Physiotherapy for arm mobility begins within 24–48 hours of surgery. Most patients return to desk work within 3–6 weeks. Nipple reconstruction — the final aesthetic step — is performed under local anaesthesia at 3–6 months. Dr. Gore's team provides a detailed individualised recovery plan and dedicated breast care nurse support.
Q65What is breast cancer in young women under 40?
Breast cancer under 40 tends to be more aggressive — higher grade, more often triple-negative or HER2-positive, frequently BRCA-associated, with higher local recurrence rates after breast-conserving surgery. BRCA testing is strongly recommended for all women under 40. Contralateral risk-reducing mastectomy may be appropriate for confirmed BRCA carriers. Fertility preservation — oocyte cryopreservation before chemotherapy — must be discussed at the first consultation, ideally within 2 weeks of diagnosis. Young women face unique challenges including body image, fertility, and relationships — specialist psychological support and peer support groups are important components of comprehensive care alongside oncological treatment.
Head & Neck Cancer Surgery
Q 66 – 80
Q66What is thyroid cancer and can it be completely cured?
Thyroid cancer arises from thyroid gland cells — the most common type is papillary thyroid cancer (PTC) with a 10-year survival exceeding 95%. Total thyroidectomy followed by radioiodine ablation is the standard curative treatment. Central neck dissection is added when lymph nodes are involved. Patients require lifelong thyroxine replacement after total thyroidectomy. The two critical structures preserved during surgery are the recurrent laryngeal nerves (protecting voice) and the parathyroid glands (preventing hypocalcaemia). Medullary thyroid cancer requires specific genetic assessment (RET mutation testing) for the patient and family. Most thyroid cancers are highly curable — even with lymph node involvement — when treated appropriately at specialist centres.
Q67What are the risks of thyroid surgery?
Two risks specific to thyroidectomy deserve attention. Recurrent laryngeal nerve injury causes hoarseness (unilateral) or breathing difficulty (bilateral, rare) — risk under 1% in experienced hands; temporary hoarseness is more common and usually resolves within weeks. Parathyroid gland damage causes hypocalcaemia — tingling, cramps, muscle spasms — managed with calcium and Vitamin D supplements; usually temporary but occasionally permanent. General surgical risks — bleeding, wound infection, haematoma — are uncommon. Most patients are discharged within 1–2 days and return to work in 1–2 weeks. Dr. Gore uses intraoperative laryngeal nerve neuromonitoring routinely to reduce RLN injury risk during all thyroid operations.
Q68Who is the best thyroid surgeon in Pune?
Dr. Vinod T. Gore has 30+ years of dedicated thyroid surgery experience including total thyroidectomy, central and lateral neck dissection for thyroid cancer, completion thyroidectomy, and complex redo thyroid surgery. Intraoperative laryngeal nerve neuromonitoring is used routinely to protect the recurrent laryngeal nerve. His thyroid surgery programme at Sahyadri Manipal Hospital Pune prioritises nerve preservation, parathyroid preservation, and oncological adequacy of lymph node dissection. Full thyroid surgery details at bestthyroidsurgeon.in. For consultation at Silver Leaf Clinic, Hadapsar: call 88558 10010. Bring thyroid ultrasound, FNAC report, thyroid function tests, and any previous neck surgery records.
Q69What are the warning signs of oral cancer?
Signs that must not be ignored: a non-healing mouth ulcer lasting more than 3 weeks; white patch (leukoplakia) or red patch (erythroplakia) on oral mucosa; unexplained loosening of teeth; difficulty opening the mouth (trismus); a lump or thickening in the tongue or floor of mouth; unexplained cervical lymph node swelling; and difficulty or pain on swallowing. Risk factors most common in India: tobacco chewing (the strongest risk factor), smoking, alcohol consumption, and betel nut use. Oral cavity cancer is highly curable when detected early — any persistent oral symptom beyond 3 weeks must be assessed by a surgeon experienced in head and neck oncology.
Q70What is neck dissection surgery?
Neck dissection removes cervical lymph nodes from the neck — performed when cancer has spread to neck nodes or prophylactically in high-risk tumours. Types: selective neck dissection removes specific node levels based on the primary tumour's drainage pattern; modified radical neck dissection removes all five nodal levels while preserving the sternomastoid muscle, internal jugular vein, and spinal accessory nerve; radical neck dissection (now rarely performed) removes these structures as well. The spinal accessory nerve supplies the trapezius muscle — its preservation is critical for shoulder function and quality of life after surgery. Neck physiotherapy begins immediately post-operatively to prevent permanent shoulder dysfunction.
Q71What is parotid gland surgery for cancer?
Malignant parotid tumours — mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma — are treated by parotidectomy. Superficial parotidectomy removes the lobe of parotid tissue superficial to the facial nerve. Total parotidectomy removes both lobes. The facial nerve — controlling all muscles of facial expression — runs through the parotid gland and is the defining technical challenge. Its identification and meticulous dissection throughout its entire course is mandatory. In tumours directly invading the nerve, sacrifice may be unavoidable — followed by immediate nerve grafting. Neck dissection is added for node-positive disease. Post-operative radiotherapy is standard for most malignant parotid tumours.
Q72What is a thyroid nodule and when does it need surgery?
A thyroid nodule is a discrete lesion within the thyroid gland — 95% are benign. Evaluation: ultrasound using TIRADS scoring assesses suspicious features (solid composition, hypoechogenicity, irregular margins, microcalcifications). FNAC biopsy is performed for suspicious or size-threshold nodules — classified by the Bethesda system (I–VI). Surgery is recommended for Bethesda IV–VI cytology; large nodules causing compression or dysphagia; retrosternal goitre; hyperfunctioning toxic nodule not responding to medical treatment; and patient preference when Bethesda III atypia is repeatedly found. Molecular testing of FNAC specimens increasingly refines the surgical decision for indeterminate nodules.
Q73What is medullary thyroid cancer and why is genetic testing essential?
Medullary thyroid cancer (MTC) arises from thyroid C-cells secreting calcitonin — the specific tumour marker. Unlike papillary and follicular cancers, MTC does not take up radioiodine, making RAI therapy ineffective. Critically, 25% of MTC cases are hereditary — caused by RET proto-oncogene mutations — occurring as Multiple Endocrine Neoplasia type 2 (MEN2A or MEN2B). All MTC patients must have RET genetic testing — a positive result mandates family screening and prophylactic thyroidectomy for affected relatives, ideally before cancer develops in childhood. Treatment: total thyroidectomy with central neck dissection. Vandetanib and cabozantinib for progressive metastatic MTC.
Q74What is radioiodine therapy after thyroid cancer surgery?
Radioactive iodine (I-131) is given after total thyroidectomy for papillary and follicular thyroid cancer — ablating residual thyroid tissue and microscopic cancer deposits. The thyroid uniquely takes up iodine — making RAI a precisely targeted treatment. Preparation: thyroid hormone withdrawal or Thyrogen injection stimulates thyroid tissue uptake before dosing. Administration: single oral capsule or drink. Temporary isolation for 2–5 days for radiation safety. Side effects are mild — transient salivary gland inflammation, nausea. Post-RAI whole body scan confirms extent of uptake. Serum thyroglobulin becomes the most sensitive long-term recurrence marker after successful ablation.
Q75What is the surgery for oral cavity cancer?
Oral cavity cancer surgery excises the primary tumour with clear margins. Reconstruction scale by defect size: small defects — secondary intention healing or split-skin graft; medium defects — pedicled flaps (pectoralis major, nasolabial flap); large defects involving jaw resection — free flaps (radial forearm free flap for oral lining; fibula free flap providing vascularised bone for mandibular reconstruction). Microsurgical free flap reconstruction — anastomosing vessels under the operating microscope — is the gold standard for major oral defects, restoring appearance, speech, and swallowing function. Simultaneous neck dissection is performed for clinically or radiologically positive cervical nodes. Post-operative radiotherapy is standard for most Stage III–IV oral cancers.
Q76What is laryngeal cancer surgery?
Laryngeal cancer treatment aims to preserve the voice whenever oncologically safe. Early glottic (vocal cord) cancer is highly curable with radiotherapy alone, preserving natural voice. Larger tumours require partial laryngectomy — supraglottic, hemilaryngectomy, or laser endoscopic resection — preserving remaining voice. Total laryngectomy removes the entire voice box creating a permanent tracheostoma — voice rehabilitation uses a tracheoesophageal prosthesis (TEP), achieving near-normal voice. The choice between radiotherapy, partial, and total laryngectomy depends on tumour site, stage, and the priority given to voice preservation versus optimal oncological clearance — decided at head and neck oncology MDT.
Q77What is HPV-associated oropharyngeal cancer?
HPV-16 is now the most common cause of oropharyngeal squamous cell carcinoma — affecting the tonsil and base of tongue — surpassing tobacco and alcohol in many countries. HPV-positive oropharyngeal cancer has a significantly better prognosis than HPV-negative disease — 5-year survival 80–85% versus 40–50%. It typically presents in non-smoking patients in their 40s–60s with a cervical lymph node as the first sign. Treatment: chemoradiation or Transoral Robotic Surgery (TORS) — allowing minimally invasive excision through the mouth, avoiding external incisions and reducing post-treatment swallowing dysfunction. De-escalation of radiation dose for HPV-positive disease is under investigation in multiple international trials.
Q78What is the recovery after thyroid surgery?
Hospital stay is 1–2 days for most thyroid operations. Temporary hoarseness is common and usually resolves within 2–4 weeks. Calcium supplementation is given routinely after total thyroidectomy — temporary hypocalcaemia (tingling, cramps) is common in the first 1–2 weeks while the parathyroid glands recover. Thyroxine (T4) replacement is started immediately and continued for life. The neck wound is closed with absorbable sutures — no suture removal needed. Most patients return to light work within 1–2 weeks and resume full activity at 3–4 weeks. Post-operative thyroid function tests at 6 weeks guide the correct thyroxine dose adjustment.
Q79What is submandibular gland cancer surgery?
Submandibular gland tumours carry a 40–50% malignancy rate — higher than parotid tumours. Adenoid cystic carcinoma is the most common malignant type, known for perineural invasion and delayed distant recurrence. Surgery: excision of the entire submandibular gland with adequate margins. Three nerves at risk during dissection: marginal mandibular branch of facial nerve (lower lip movement), lingual nerve (tongue sensation), and hypoglossal nerve (tongue movement). Careful identification and preservation of these nerves is the primary technical priority. Post-operative radiotherapy is standard for all malignant submandibular gland tumours regardless of margin status.
Q80What is parathyroid surgery?
Parathyroidectomy removes overactive parathyroid glands for primary hyperparathyroidism — almost always from a benign adenoma — or the rare parathyroid carcinoma. Benign adenoma: minimally invasive parathyroidectomy guided by sestamibi scan; intraoperative PTH monitoring confirms cure when PTH drops by more than 50% after gland removal. Parathyroid carcinoma: en bloc resection with ipsilateral thyroid lobe and involved lymph nodes — wider surgery than for benign disease, to achieve clear margins. Localisation uses ultrasound, sestamibi scan, and 4D-CT. Recurrence is common in carcinoma — long-term medical management of hypercalcaemia with bisphosphonates and cinacalcet is required.
GI & HPB Cancer Surgery
Q 81 – 110
Q81What is the Whipple procedure (pancreaticoduodenectomy)?
The Whipple procedure removes the pancreatic head, duodenum, distal bile duct, gallbladder, and often the distal stomach — for cancers of the pancreatic head, ampulla of Vater, distal bile duct, or periampullary duodenum. Three anastomoses are then constructed: pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy. The operation takes 5–8 hours with hospital stay of 7–10 days at specialist centres. Five-year survival after R0 Whipple for pancreatic cancer is 20–25%; for periampullary cancers (ampullary, bile duct, duodenal) survival reaches 40–60%. Dr. Gore performs robotic Whipple surgery at Sahyadri Manipal Hospital, Pune — achieving equivalent oncological clearance with less blood loss than the open approach.
Q82What is TME (Total Mesorectal Excision) for rectal cancer?
TME — introduced by Professor Bill Heald in 1982 — is the surgical technique that transformed rectal cancer outcomes worldwide. Sharp dissection along the embryological fascial plane surrounding the mesorectum removes the rectum as an intact, unbroken specimen package — preserving the autonomic nerve plexuses responsible for bladder and sexual function. Before TME, local recurrence was 25–40%. With quality TME at specialist centres, local recurrence is now under 5%. Robotic surgery is the preferred approach for TME — providing visual clarity in the narrow pelvis necessary for consistent, high-quality mesorectal dissection and reliable nerve preservation in every case.
Q83What is Low Anterior Resection (LAR) for rectal cancer?
LAR removes the rectum for cancer while preserving the anal sphincter — the bowel is reconnected to the anus or anal canal. A temporary loop ileostomy protects the join during healing and is reversed at 8–12 weeks after X-ray confirmation of healing. LAR is the standard operation for mid and low rectal cancers where the sphincter can be preserved with clear oncological margins. Robotic LAR achieves sphincter preservation in a higher proportion of patients than open surgery — particularly in male patients with a narrow pelvis where open access is most limited. Most patients with rectal cancer can avoid a permanent stoma with current robotic surgical techniques.
Q84What is Abdominoperineal Resection (APR) and when is it necessary?
APR removes the rectum, anus, and entire sphincter complex — creating a permanent sigmoid colostomy. It is required when the tumour directly invades the sphincter with no possibility of clear margin preservation; when the tumour is at or below the dentate line with no functional sphincter to preserve; or when severe pre-existing incontinence makes sphincter preservation clinically meaningless. Robotic ELAPE (Extralevator APR) achieves a wider cylindrical resection with lower positive circumferential margin rates. Perineal reconstruction using a VRAM flap — recommended for patients who have received pelvic chemoradiation — prevents wound breakdown. Patients should seek specialist review before accepting an APR recommendation.
Q85What is sphincter preservation in rectal cancer surgery?
Sphincter preservation is the goal of modern rectal cancer surgery — avoiding a permanent stoma by removing the cancer while keeping the anal sphincter complex intact. Key enablers: neoadjuvant chemoradiation shrinks low rectal tumours and reduces T-stage; robotic TME in the narrow pelvis with 10x 3D vision allows dissection within millimetres of the sphincter; intersphincteric resection (ISR) removes the internal sphincter alone while preserving the external sphincter, enabling coloanal anastomosis in very low tumours. At experienced robotic centres, the percentage of patients requiring permanent stoma (APR) has fallen significantly. Patients told they need an APR should obtain a second specialist opinion before proceeding.
Q86What is a stoma and how is it managed?
A stoma is a surgically created opening in the abdominal wall through which the bowel empties into a sealed bag on the body. In rectal cancer surgery, a temporary loop ileostomy protects the bowel join during healing — reversed at 8–12 weeks. An end colostomy after APR is permanent. Management: bag changes every 2–3 days; measure the stoma correctly and cut the bag 2–3mm larger than the stoma; maintain peristomal skin health with barrier products. Ileostomy patients must drink 2–2.5 litres daily — dehydration is the most common and preventable complication. A dedicated stoma nurse provides training before hospital discharge. Full guidance at cancerclinicpune.com. Call 88558 10010 for stoma nurse consultation.
Q87What is LARS syndrome after rectal cancer surgery?
LARS (Low Anterior Resection Syndrome) is bowel dysfunction after sphincter-preserving rectal cancer surgery — frequent loose bowel movements (10–20 daily initially), urgency, incomplete evacuation, clustering, and occasional incontinence. It affects 40–60% of LAR patients to some degree. Management: dietary modification (low-residue diet, regular meal timing); loperamide taken before meals to slow transit; pelvic floor physiotherapy; biofeedback retraining; transanal irrigation — water instilled via catheter to evacuate the rectum on demand; and sacral nerve stimulation for severe refractory cases. LARS improves significantly over 12–24 months as the neorectum adapts. Detailed LARS management guidance at cancerclinicpune.com.
Q88What is stoma reversal and when can it be performed?
Stoma reversal restores normal bowel continuity after the temporary loop ileostomy — performed after confirming the anastomosis has healed on gastrografin enema or flexible sigmoidoscopy at 8 weeks, and after completing any planned adjuvant chemotherapy. The operation takes 1–2 hours laparoscopically — the stoma loop is freed, both bowel limbs are anastomosed, and bowel is returned to the abdomen. Hospital stay is 3–5 days. After reversal, frequent loose stools (LARS) are expected initially — managed with diet, loperamide, and physiotherapy. Not all stomas can be reversed — anastomotic complication, patient fitness, or tumour recurrence may prevent it. Eligibility is reviewed at every post-operative follow-up.
Q89What is gastric cancer surgery (gastrectomy)?
Gastrectomy removes all or part of the stomach for gastric cancer — distal gastrectomy for antral and pyloric tumours, total gastrectomy for body and fundus tumours — with complete D2 lymph node dissection. D2 lymphadenectomy is the international quality standard. Neoadjuvant FLOT chemotherapy is given before surgery for Stage II–III gastric cancer, significantly improving survival. Staging laparoscopy before definitive surgery excludes peritoneal deposits not visible on CT — changing management in 15–30% of cases. Robotic D2 gastrectomy achieves equivalent nodal clearance to open surgery with significantly less blood loss and faster recovery. Reconstruction uses Billroth II or Roux-en-Y gastrojejunostomy depending on the extent of gastric resection.
Q90What is esophagectomy for oesophageal cancer?
Esophagectomy removes the oesophagus for cancer — the stomach is fashioned into a gastric conduit to replace it, connected to the remaining upper oesophagus or pharynx. Standard neoadjuvant treatment: CROSS protocol (carboplatin, paclitaxel, 41.4 Gy radiotherapy) achieving pathological complete response in 25–30%. RAMIE — Robotic Assisted Minimally Invasive Esophagectomy — is Dr. Gore's preferred approach. ICG fluorescence confirms gastric conduit blood supply before anastomosis, preventing conduit tip ischaemia. RAMIE achieves lower pulmonary complication rates and shorter ICU stay than open thoracotomy. Full recovery takes 6–8 weeks. Dr. Gore has a dedicated Research Fellowship in Thoracic Oncology from Tata Memorial Hospital Mumbai.
Q91What is GIST tumour and how is it treated?
GIST (Gastrointestinal Stromal Tumour) arises from interstitial cells of Cajal — defined by KIT or PDGFRA gene mutations. Surgery: R0 resection with intact tumour capsule — tumour rupture converts potentially curable GIST to peritoneal sarcomatosis and must be absolutely avoided. No lymph node dissection is needed (GISTs spread haematogenously, not via lymphatics). KIT/PDGFRA molecular testing is mandatory before starting imatinib (Gleevec) — the targeted therapy that blocks the mutated KIT pathway, achieving response in over 80% of KIT exon 11 mutations. PDGFRA D842V mutation is imatinib-resistant requiring avapritinib. High-risk resected GISTs receive 3 years adjuvant imatinib (SSGXVIII trial).
Q92What is hepatectomy for liver cancer and metastases?
Hepatectomy removes one or more liver segments — for primary liver cancer (HCC, cholangiocarcinoma) or metastases (colorectal, NET). The liver has eight Couinaud segments; major hepatectomy removes three or more. Critical requirement: adequate Future Liver Remnant (FLR) — minimum 20–25% for a healthy liver, 30–40% after preoperative chemotherapy, 40% or more for a cirrhotic liver. CT volumetry calculates FLR precisely. Portal Vein Embolisation (PVE) hypertrophies the FLR when borderline. ICG fluorescence maps segment boundaries for precise anatomical resection and detects occult metastases not visible on CT or MRI. The liver regenerates fully within 4–6 weeks after major resection.
Q93Can colorectal liver metastases be cured with surgery?
Yes — this is one of the most important messages in GI oncology. Surgical resection of colorectal liver metastases (CRLM) achieves 30–50% five-year survival — the only treatment offering genuine long-term cure. Fewer than 20% of CRLM patients are initially resectable. Chemotherapy conversion (FOLFOX or FOLFIRI plus bevacizumab or cetuximab) converts a further 15–25% to resectable. Many patients labelled inoperable at general hospitals are successfully resected by specialist HPB surgeons after detailed imaging review. A second opinion from an experienced HPB surgical oncologist reviewing the actual CT images — not just the radiology report — is essential before accepting palliative intent for colorectal liver metastases.
Q94What is anal canal cancer treatment?
Anal canal squamous cell carcinoma is primarily treated with chemoradiation — the Nigro protocol (5-FU plus Mitomycin C plus 50–60 Gy radiotherapy) achieves complete clinical response in 60–80% of patients, preserving the anus and sphincter without surgery. Surgery (APR) is reserved for residual disease at 26 weeks or confirmed local recurrence — making anal canal cancer one of very few GI cancers where chemoradiation rather than surgery is the primary curative treatment. HPV-16 and HPV-18 cause over 85% of anal cancers — it is a vaccine-preventable cancer. Any persistent perianal symptom including bleeding must be examined promptly — anal cancer is frequently and dangerously misdiagnosed as haemorrhoids.
Q95What is cholangiocarcinoma (bile duct cancer) surgery?
Cholangiocarcinoma is classified by location: intrahepatic — treated by hepatectomy with adequate margins; perihilar or Klatskin tumour at the bile duct bifurcation — the most complex, often requiring extended hepatectomy, bile duct excision, and portal vein reconstruction; distal — treated by Whipple procedure. Only 30–40% are resectable at diagnosis. Adjuvant capecitabine (BILCAP trial) is recommended after R0 resection. For unresectable disease: gemcitabine plus cisplatin plus durvalumab (first-line immunotherapy combination). FGFR2 inhibitors (pemigatinib) for FGFR2-rearranged intrahepatic cholangiocarcinoma — molecular testing is mandatory at diagnosis. Biliary stenting relieves jaundice in unresectable perihilar disease pending systemic treatment.
Q96What are the warning signs of colorectal cancer?
Warning signs requiring urgent colonoscopic investigation: rectal bleeding — any blood in stool in an adult must be investigated, never assumed to be haemorrhoids; change in bowel habit lasting more than 3 weeks (increased frequency, looser stools, or new constipation); passage of mucus per rectum; sensation of incomplete evacuation; unexplained iron deficiency anaemia (right-sided colon cancer bleeds slowly causing anaemia without visible blood); unexplained significant weight loss; and lower abdominal cramps. Early colorectal cancer is frequently asymptomatic — detectable only by colonoscopic screening. Any persistent symptom beyond 4 weeks warrants prompt colonoscopy referral.
Q97What is pancreatic cancer surgery and what is the outlook?
Surgical resection is the only curative treatment for pancreatic cancer — available for 15–20% of patients at diagnosis. Whipple procedure for head tumours; distal pancreatectomy for body/tail tumours. FOLFIRINOX or gemcitabine plus nab-paclitaxel are given as 6 months of adjuvant chemotherapy after surgery. Borderline resectable tumours — abutting but not encasing the superior mesenteric artery — may become resectable after neoadjuvant chemotherapy. Five-year survival after R0 Whipple is 20–25%; node-negative R0 disease achieves 35–40%. BRCA-mutant pancreatic cancer responds to PARP inhibitors (olaparib) as maintenance — germline genetic testing is recommended for all pancreatic cancer patients.
Q98What is D3 lymphadenectomy (Complete Mesocolic Excision) for colon cancer?
D3 lymphadenectomy — Complete Mesocolic Excision (CME) with central vascular ligation — is the oncological gold standard for colon cancer, analogous to what TME achieves for rectal cancer. Sharp dissection along the embryological fascial plane surrounding the mesocolon, combined with high ligation of the feeding artery at its origin, maximises nodal yield and reduces local recurrence. Studies show CME achieves 15–20% higher five-year survival in Stage III colon cancer versus conventional colectomy. Robotic colon surgery facilitates high-quality CME with intracorporeal anastomosis. This is the standard surgical approach in Dr. Gore's robotic colorectal programme at Sahyadri Manipal Hospital Pune.
Q99What is neuroendocrine tumour (NET) surgery?
Surgery is the only curative treatment for NETs. Approach by site: appendiceal NET under 2cm — appendicectomy alone (curative in over 95%); appendiceal NET above 2cm — right hemicolectomy; ileal NET — wide segmental resection with mesenteric lymphadenectomy; rectal NET under 1cm — endoscopic resection; rectal NET above 2cm — formal LAR; insulinoma — enucleation (most are small and benign); non-functional pancreatic NET above 2cm — distal pancreatectomy or Whipple. Liver metastases: resection and ablation where feasible, TACE or SIRT for liver-dominant disease. Octreotide LAR must be given before any surgery in functional NET patients to prevent carcinoid crisis during anaesthesia.
Q100What is Watch and Wait for rectal cancer after chemoradiation?
Watch and Wait (Organ Preservation) is a management strategy for rectal cancer patients achieving complete clinical response (cCR — no detectable tumour on examination, MRI, and endoscopy) after neoadjuvant chemoradiation. Instead of proceeding to surgery, these patients enter intensive surveillance: clinical examination and MRI every 3 months for 2 years. Local regrowth occurs in 15–25% — salvaged by surgery in most cases. Watch and Wait avoids major pelvic surgery and potential permanent stoma in carefully selected patients. It requires specialist centre assessment, confirmed complete clinical response (not near-complete response), and committed long-term surveillance. Dr. Gore provides Watch and Wait management within his rectal cancer programme at Sahyadri Manipal Hospital.
Q101What is HCC (Hepatocellular Carcinoma) treatment?
HCC arises from hepatocytes — most commonly in a cirrhotic liver from Hepatitis B, Hepatitis C, or NAFLD. Staged by BCLC system combining tumour extent, liver function, and performance status. Treatment: surgical resection for BCLC-A in Child-Pugh A patients; liver transplantation within Milan criteria (single nodule under 5cm or three nodules under 3cm) for cirrhotic patients unsuitable for resection; TACE (Transarterial Chemoembolisation) for intermediate BCLC-B stage; atezolizumab plus bevacizumab (IMbrave150 trial) or sorafenib for advanced stage. AFP monitoring detects recurrence. All cirrhotic patients should have 6-monthly liver ultrasound and AFP — the most effective HCC surveillance strategy for early detection.
Q102What is Pseudomyxoma Peritonei (PMP) and how is it treated?
PMP is a rare condition where mucus-secreting tumour cells — almost always from a low-grade appendiceal mucinous neoplasm (LAMN) — progressively fill the peritoneal cavity with mucinous material. PMP grows very slowly, rarely causes systemic metastases, and the patient's general health can remain well preserved despite large peritoneal volumes. Treatment: CRS+HIPEC — complete peritonectomy procedures removing all peritoneal surfaces followed by HIPEC. Five-year survival after complete CRS+HIPEC for low-grade PMP is 80–90% — one of the best outcomes in peritoneal cancer surgery. Without treatment, PMP is eventually fatal from bowel obstruction. Any patient with a mucinous appendiceal tumour must be referred to a CRS/HIPEC specialist centre for review.
Q103What is Lynch syndrome and how does it affect colorectal cancer management?
Lynch syndrome — caused by germline mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2) — accounts for approximately 3% of all colorectal cancers. Lifetime risks: colorectal cancer 50–80%; endometrial cancer 30–60%; ovarian, gastric, urological, and biliary cancers also elevated. All colorectal cancers should be tested for mismatch repair deficiency by IHC — dMMR/MSI-high tumours are candidates for immunotherapy (pembrolizumab) and respond dramatically better than MMR-proficient tumours. Lynch syndrome patients are recommended extended colectomy (subtotal) to reduce metachronous cancer risk. First-degree relatives carry a 50% mutation risk — genetic counselling and testing are essential.
Q104What is appendiceal cancer surgery?
Appendiceal cancers range from carcinoid tumours (most under 2cm, curative with appendicectomy alone) to mucinous neoplasms including LAMN and mucinous adenocarcinoma. Right hemicolectomy is performed for appendiceal carcinoids above 2cm, adenocarcinoma, and goblet cell carcinoids. LAMN rupturing seeds mucus-secreting cells throughout the peritoneum — producing PMP. PMP is treated with CRS+HIPEC — five-year survival of 80–90% for low-grade PMP with complete cytoreduction. Diagnosis of mucinous appendiceal tumour is often made incidentally at appendicectomy — the pathology report must be carefully reviewed. Any patient with a mucinous appendiceal tumour should be referred to a HIPEC specialist centre for MDT review.
Q105What is distal pancreatectomy with splenectomy?
Distal pancreatectomy removes the body and tail of the pancreas together with the spleen — for cancers of the pancreatic body and tail. Unlike Whipple surgery, no reconstruction is needed — the pancreatic stump is closed by stapler or suture. The most feared complication is pancreatic fistula — leakage from the stump — occurring in 15–25% but usually managed conservatively with drains and octreotide. RAMPS (Radical Antegrade Modular Pancreatosplenectomy) — dissecting from medial to lateral — addresses the retroperitoneal margin first, achieving higher R0 rates. Robotic distal pancreatectomy achieves equivalent oncological clearance to open surgery with significantly less blood loss and faster recovery.
Q106What is radiofrequency and microwave ablation for liver tumours?
RFA (Radiofrequency Ablation) and MWA (Microwave Ablation) destroy liver tumours using heat delivered through a needle under CT or ultrasound guidance. Most effective for tumours under 3cm not adjacent to major vessels. Performed percutaneously, laparoscopically, or open. ICG fluorescence after ablation confirms the zone completely covers the tumour — preventing incomplete ablation and local recurrence. MWA produces larger ablation zones and is less affected by the heat-sink effect of adjacent vessels — increasingly preferred over RFA for colorectal liver metastases. Local recurrence rate (10–20%) is higher than surgical resection (under 5%) — ablation is used when resection is not feasible due to patient fitness or tumour location.
Q107What is TACE (Transarterial Chemoembolisation) for liver cancer?
TACE delivers chemotherapy — doxorubicin or cisplatin — combined with embolic agents through the hepatic artery into vessels supplying the tumour, cutting off blood supply while achieving high local drug concentrations. It is the primary locoregional treatment for intermediate-stage HCC (BCLC-B) and is used for unresectable NET liver metastases. Prerequisites: preserved liver function (Child-Pugh A or B7); no main portal vein thrombosis. Drug-eluting bead TACE (DEB-TACE) releases chemotherapy slowly, improving drug delivery and reducing systemic side effects. TACE can downstage HCC to within transplant criteria — bridging patients to liver transplantation while waiting. Repeated TACE sessions are performed as disease progresses.
Q108What is staging laparoscopy for gastric cancer?
Staging laparoscopy is recommended for all locally advanced gastric cancer (T3/T4 on CT) before definitive surgery or neoadjuvant chemotherapy. Under brief general anaesthesia, the peritoneal cavity is inspected — detecting surface deposits, liver nodules, and omental seeding not visible on CT imaging. Peritoneal washing cytology is collected — positive cytology (even without visible deposits) upstages the patient to Stage IV, changing management from curative surgery to systemic chemotherapy. Staging laparoscopy identifies occult peritoneal disease in 15–30% of patients deemed resectable on CT — preventing unnecessary major laparotomy in these patients. A 30–45 minute procedure with disproportionately high clinical value for treatment planning.
Q109What is colorectal cancer screening and who needs a colonoscopy?
Colorectal cancer screening is the most effective way to prevent advanced cancer — colonoscopy detects pre-cancerous polyps and removes them before they develop into invasive cancer. Average-risk individuals: colonoscopy every 10 years from age 45. High-risk individuals (family history of colorectal cancer, Lynch syndrome, FAP, personal history of polyps) need colonoscopy from age 35–40 or 10 years before the youngest affected relative. Symptoms warranting urgent colonoscopy: rectal bleeding, altered bowel habit over 3 weeks, unexplained anaemia, or palpable abdominal mass. Faecal immunochemical test (FIT) annually is an alternative for those unable to have colonoscopy. Silver Leaf Clinic, Hadapsar provides cancer risk assessment. Call 88558 10010.
Q110What is the surgery for gallbladder cancer?
Gallbladder cancer is often discovered incidentally after laparoscopic cholecystectomy for presumed stones — the pathology report revealing unexpected cancer. Management depends on T-stage: T1a (limited to mucosa) — simple cholecystectomy is adequate. T1b (into muscle layer) — simple cholecystectomy may suffice; extended resection debated. T2 (into perimuscular connective tissue) — extended cholecystectomy with en bloc resection of liver segments IVb and V plus hepatoduodenal ligament lymphadenectomy is the standard. T3/T4 — extended hepatectomy and bile duct resection if involved. Laparoscopic cholecystectomy for gallbladder cancer (before diagnosis is known) carries a port-site metastasis risk — re-exploration is recommended for T2 and above. R0 resection is the only curative treatment.
🌡️
HIPEC Surgery
Q 111 – 125
Q111What is HIPEC surgery and how does it work?
HIPEC — Hyperthermic Intraperitoneal Chemotherapy — is a two-phase surgical procedure. Phase 1, Cytoreductive Surgery (CRS): the surgeon systematically removes all visible peritoneal tumour deposits — stripping peritoneum from abdominal surfaces, diaphragm, and pelvic floor; resecting involved bowel and organs — aiming for CC-0 (no visible residual tumour). Phase 2, HIPEC: heated chemotherapy (41–43°C) is circulated through catheters in the closed abdomen for 30–90 minutes — treating remaining microscopic cancer cells. The rationale: direct heated instillation achieves 20–25 times the local drug concentration of systemic IV chemotherapy, which cannot penetrate the peritoneal barrier adequately. CRS+HIPEC takes 8–14 hours, requires 1–2 days ICU, and 10–14 days total hospital stay.
Q112What is the PCI score and how does it determine HIPEC eligibility?
PCI (Peritoneal Cancer Index) quantifies peritoneal tumour burden — dividing the abdomen into 13 regions each scored 0–3 by tumour nodule size. Maximum PCI is 39. A lower PCI predicts greater benefit from CRS+HIPEC: PCI under 15–20 for colorectal peritoneal metastases; PCI under 15 for gastric peritoneal disease; higher thresholds are acceptable for appendiceal PMP which has very favourable biology. PCI is assessed on preoperative CT and confirmed at staging laparoscopy before committing to full CRS. A very high PCI where CC-0 is not achievable means HIPEC is unlikely to benefit — the 10–14 hour major operation cannot be justified without prospect of complete cytoreduction.
Q113What cancers can be treated with HIPEC?
HIPEC is indicated for peritoneal metastases from: colorectal cancer — the most common indication, PCI under 15–20, five-year survival 25–35% after CC-0 resection; appendiceal cancer and Pseudomyxoma Peritonei — the most favourable indication, five-year survival 80–90%; ovarian cancer — HIPEC added to interval debulking surgery (OVHIPEC trial) improves overall survival by 12 months; primary peritoneal mesothelioma — excellent response; and selected gastric cancer with very limited peritoneal involvement at specialist centres. HIPEC is not appropriate for extensive systemic metastases (liver, lung), very high PCI where CC-0 is not achievable, or poor patient performance status precluding major surgery.
Q114What drugs are used in HIPEC chemotherapy?
Chemotherapy choice depends on primary tumour histology: colorectal peritoneal metastases — oxaliplatin (30-minute instillation, most widely used) or mitomycin C (90 minutes, used in the original French Elias protocol); appendiceal cancer and PMP — mitomycin C with or without doxorubicin; ovarian cancer — cisplatin with or without paclitaxel (OVHIPEC trial used cisplatin); mesothelioma — cisplatin plus doxorubicin. The drug is heated to 41–43°C before circulation. Heating has dual benefits: increased cell membrane permeability enhancing drug uptake into cancer cells, and direct cytotoxic effects — cancer cells are more sensitive to hyperthermia than normal cells. Renal function requires close monitoring throughout cisplatin-based HIPEC.
Q115Is HIPEC curative or palliative?
HIPEC is potentially curative — not merely palliative — in appropriately selected patients. When peritoneal disease is limited (low PCI), CC-0 cytoreduction is achievable, there are no systemic metastases beyond the peritoneum, and the primary tumour has favourable biology, CRS+HIPEC achieves genuine long-term cure. Five-year survival: colorectal peritoneal metastases 25–35%; appendiceal PMP 80–90%; ovarian cancer improved by 12 months (OVHIPEC trial). In patients where CC-0 is not achievable, the surgery becomes palliative in intent — and the risk-benefit ratio of a 10–14 hour operation needs careful consideration. This nuanced discussion is provided at HIPEC consultation at Silver Leaf Clinic Pune. Call 88558 10010.
Q116What is the CC score in HIPEC surgery?
CC (Completeness of Cytoreduction) score quantifies residual disease after CRS — the strongest single predictor of survival after CRS+HIPEC. CC-0: no visible residual disease — the essential goal for curative intent. CC-1: residual nodules under 2.5mm — within the penetration depth of HIPEC chemotherapy. CC-2: nodules 2.5mm to 2.5cm. CC-3: nodules above 2.5cm. Survival benefit from HIPEC is realised only after CC-0 (and possibly CC-1) resection — CC-2 and CC-3 residual disease is not effectively addressed by chemotherapy penetration alone. This is why careful preoperative PCI assessment is critical — CC-0 must be achievable before committing the patient to the major surgery and morbidity of CRS+HIPEC.
Q117What is Pseudomyxoma Peritonei (PMP) and why is HIPEC so effective?
PMP is a rare condition where mucus-secreting tumour cells — almost always from a LAMN (Low-grade Appendiceal Mucinous Neoplasm) — progressively fill the peritoneal cavity with mucinous material. PMP has unique biology: it grows very slowly, remains confined to the peritoneum for years, rarely causes systemic metastases, and the patient's general health can remain remarkably well despite large peritoneal volumes. CRS+HIPEC achieves five-year survival of 80–90% for low-grade PMP after complete peritonectomy — one of the best survival outcomes in peritoneal cancer surgery. Without specialist treatment PMP is eventually fatal from bowel obstruction and nutritional failure. Any patient with a mucinous appendiceal tumour must be referred to a HIPEC specialist centre.
Q118What is HIPEC for ovarian cancer?
The OVHIPEC trial (van Driel et al., NEJM 2018) established HIPEC for ovarian cancer — demonstrating that adding cisplatin HIPEC to interval debulking surgery (after 3 cycles of neoadjuvant carboplatin-paclitaxel) significantly improved recurrence-free survival (10.7 vs 8.4 months) and overall survival (45.7 vs 33.9 months) without increasing serious adverse events in Stage IIIC ovarian cancer. HIPEC at IDS is most beneficial when CC-0 debulking is achieved. The 12-month survival improvement is clinically meaningful in a disease where overall survival after recurrence has historically been measured in months. HIPEC for ovarian cancer is offered at Sahyadri Manipal Hospital Pune following MDT review for eligible patients.
Q119What is the recovery after CRS+HIPEC surgery?
Recovery from CRS+HIPEC is one of the most demanding post-operative courses in abdominal surgery reflecting the 8–14 hour operative duration. ICU phase (1–2 days): cardiovascular monitoring, fluid balance, kidney function (especially with cisplatin-based HIPEC). High dependency phase (2–5 days): progressive mobilisation, drain removal, transition to oral fluids. Ward phase (5–10 days): progression to soft diet, supervised physiotherapy, wound care. Hospital discharge at 10–14 days. Home recovery: 6–8 weeks before returning to desk work; 10–12 weeks for physical roles. Fatigue dominates for 4–8 weeks. Pre-operative nutritional optimisation — correcting malnutrition common in peritoneal disease — significantly improves post-operative recovery.
Q120Is HIPEC available in Pune?
Yes. Dr. Vinod T. Gore performs CRS+HIPEC at Sahyadri Manipal Hospital, Hadapsar, Pune — one of very few specialist HIPEC centres in western India. The programme treats colorectal peritoneal metastases, appendiceal cancer and Pseudomyxoma Peritonei, ovarian cancer with peritoneal disease, and primary peritoneal mesothelioma. Every HIPEC candidate is assessed at MDT with complete preoperative staging including CT volumetric PCI assessment and staging laparoscopy before any recommendation is made. For HIPEC consultation at Silver Leaf Clinic, Hadapsar: call 88558 10010 or WhatsApp 84118 08284. Bring full CT staging, histopathology, and details of all prior chemotherapy regimens to the first appointment.
Q121What nutritional preparation is needed before HIPEC?
Nutritional preparation before CRS+HIPEC is critical — peritoneal disease patients commonly have significant malnutrition, low serum albumin, and muscle wasting from ascites and malabsorption. Standard preparation: immunonutrition supplements (arginine, omega-3, nucleotides) for 5–7 days; high-protein oral supplementation to correct hypoalbuminaemia; carbohydrate loading the night before and morning of surgery. Severely malnourished patients require 7–14 days of parenteral or enteral nutrition before surgery can proceed safely. Adequate nutritional preparation directly reduces post-HIPEC complication rates and ICU duration. A clinical dietitian experienced in peritoneal disease nutrition works with Dr. Gore's team at Sahyadri Manipal Hospital to assess and optimise every HIPEC patient pre-operatively.
Q122What is the difference between HIPEC and PIPAC?
HIPEC and PIPAC are both intraperitoneal chemotherapy techniques with fundamentally different intents. HIPEC: potentially curative; combined with maximal CRS aiming for CC-0; large volume heated liquid chemotherapy circulated for 30–90 minutes; single 8–14 hour major operation. PIPAC (Pressurised Intraperitoneal Aerosol Chemotherapy): palliative; delivers aerosolised chemotherapy laparoscopically under pressure without major cytoreduction; suitable for patients with extensive peritoneal disease not amenable to CC-0 or those unfit for CRS+HIPEC; repeated at 6–8 week intervals. HIPEC is the established standard of care with level-one evidence; PIPAC remains investigational at selected centres. Their patient populations, goals, and survival outcomes differ fundamentally.
Q123Can HIPEC be repeated for recurrent peritoneal disease?
Repeat CRS+HIPEC for recurrent peritoneal disease is performed at selected specialist centres in carefully chosen patients. Requirements for repeat HIPEC are more stringent: full recovery from the first procedure (typically over 12 months); limited recurrence technically resectable with CC-0; adequate organ reserve after the first major operation; and favourable biology suggesting benefit from re-operation. Surgical complexity is significantly greater at re-operation due to adhesions from prior peritonectomy — increasing bowel injury risk. Published data from experienced HIPEC centres show meaningful survival benefit in carefully selected repeat HIPEC patients. This decision requires comprehensive MDT review at a centre with specific expertise in redo peritoneal surgery.
Q124What is the Sugarbaker technique in HIPEC surgery?
The Sugarbaker technique — developed by Dr. Paul Sugarbaker — defines the systematic approach to cytoreductive surgery for peritoneal malignancy. It describes six standard peritonectomy procedures addressing all six parietal peritoneal surfaces: greater omentectomy and splenectomy; left upper quadrant peritonectomy; right upper quadrant peritonectomy; lesser omentectomy; pelvic peritonectomy with rectosigmoid resection; and right colectomy when the caecum is involved. Visceral resections are added based on disease distribution at the time of surgery. The CC scoring system — CC-0 through CC-3 — was developed by Sugarbaker to quantify residual disease. His establishment of HIPEC with CRS fundamentally changed the management of peritoneal surface malignancy globally. These principles form the basis of the HIPEC programme at Sahyadri Manipal Hospital Pune.
Q125How do I know if I am suitable for HIPEC surgery?
HIPEC suitability requires assessment in three domains. Oncological: peritoneal disease from an appropriate primary tumour (colorectal, appendiceal, ovarian, mesothelioma); no systemic metastases; PCI within the beneficial range (under 15–20 for colorectal); stable or responding to chemotherapy. Technical: CC-0 cytoreduction achievable on preoperative CT and confirmed at staging laparoscopy — all visible deposits can be surgically removed. Patient fitness: good performance status (ECOG 0–1); adequate kidney function for cisplatin-based HIPEC; nutritional status allowing recovery from 8–14 hour surgery; absence of prohibitive medical comorbidities. Call 88558 10010 or WhatsApp 84118 08284 to book a HIPEC suitability consultation at Silver Leaf Clinic, Hadapsar, Pune.
Gynaecological Cancers
Q 126 – 140
Q126What is ovarian cancer surgery?
Ovarian cancer surgery — staging laparotomy and primary debulking — removes all visible tumour and confirms staging. Standard components: total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic and para-aortic lymph node sampling, peritoneal biopsies, and cytological washings. Extended surgery (diaphragmatic stripping, bowel resection, splenectomy) is performed if needed to achieve CC-0. Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is used when primary debulking cannot achieve CC-0 or the patient is too frail. HIPEC at interval debulking surgery (OVHIPEC trial) improves survival by 12 months. The completeness of surgical debulking is the single most powerful determinant of ovarian cancer survival.
Q127What is radical hysterectomy for cervical cancer?
Radical hysterectomy (Wertheim's) removes the uterus, cervix, upper vagina (2–3cm), and parametria with bilateral pelvic lymphadenectomy — providing wider lateral clearance than simple hysterectomy. It is standard for Stage IB1, IB2, and selected IIA cervical cancer. Robotic radical hysterectomy achieves equivalent oncological outcomes with less blood loss, shorter hospital stay (1–3 vs 5–7 days), and faster recovery. The LACC trial (2018) identified specific technical modifications needed for minimally invasive approach — avoidance of uterine manipulator and use of colpotomy bag — which are used in Dr. Gore's programme to ensure oncological equivalence to open surgery at every procedure.
Q128What are the signs of ovarian cancer?
Ovarian cancer symptoms are non-specific and often attributed to benign conditions. Persistent symptoms lasting more than 3 weeks: abdominal bloating not related to food; early satiety — feeling full quickly; pelvic or abdominal pain; urinary urgency or frequency without infection; unexplained fatigue; and back pain. Any woman with these persistent symptoms should have a pelvic examination, CA-125 blood test, and transvaginal ultrasound. Risk factors: BRCA1/2 mutations, family history of ovarian cancer, Lynch syndrome, endometriosis, and nulliparity. Oral contraceptives reduce ovarian cancer risk by 30–50% with prolonged use. Early diagnosis transforms prognosis dramatically — screening awareness is critical for every woman.
Q129What is endometrial cancer surgery?
Endometrial cancer is treated with total hysterectomy and bilateral salpingo-oophorectomy plus sentinel node biopsy or pelvic lymphadenectomy. Robotic surgery is the preferred approach — equivalent oncological outcomes to open surgery with significantly less blood loss (200ml vs 800ml), shorter hospital stay (2 vs 5 days), and faster recovery. High-risk endometrial cancers (Grade 3, non-endometrioid histology, deep myometrial invasion) require more extensive lymphadenectomy and post-operative radiotherapy and/or chemotherapy (carboplatin-paclitaxel). Post-menopausal bleeding — the most reliable early symptom — must be investigated with endometrial biopsy promptly. Most endometrial cancers are diagnosed at Stage I with 5-year survival exceeding 90%.
Q130What is cytoreductive debulking surgery for ovarian cancer?
Cytoreductive surgery for ovarian cancer removes all visible tumour deposits — CC-0. The extent of surgery required varies enormously: from straightforward hysterectomy and omentectomy in early disease to complex multi-organ resection (diaphragmatic peritonectomy, splenectomy, bowel resection, liver resection, HIPEC) in advanced Stage IIIC disease. The single most powerful determinant of ovarian cancer survival is completeness of cytoreduction — CC-0 achieves median survival of 55–65 months in Stage IIIC; residual disease above 1cm achieves only 30–35 months. Primary debulking is preferred when CC-0 is achievable; interval debulking after neoadjuvant chemotherapy is used when primary surgery would leave residual disease.
Q131What is the survival rate for ovarian cancer?
Ovarian cancer survival is closely tied to stage at diagnosis and completeness of surgical debulking. Stage I (confined to ovary): 5-year survival 85–90% — but only 15% of cases are diagnosed this early. Stage II: 70–75%. Stage IIIC (the most common presentation): 30–40% with specialist surgery and chemotherapy; improved to 42% with HIPEC addition (OVHIPEC trial). Stage IV: 15–25%. The wide survival range within Stage IIIC — 20% to 55% — reflects the enormous impact of surgical expertise and CC-0 achievement. BRCA-mutant ovarian cancer has better prognosis — more sensitive to platinum chemotherapy and responds to PARP inhibitor maintenance (olaparib, niraparib).
Q132What are the signs of cervical cancer?
Cervical cancer warning signs: postcoital bleeding — the most characteristic symptom, occurring after sexual intercourse; irregular vaginal bleeding between periods; post-menopausal vaginal bleeding; offensive or blood-stained vaginal discharge; pelvic pain; and in advanced disease, back pain and leg swelling from lymph node compression. HPV — particularly HPV-16 and HPV-18 — causes over 95% of cervical cancers. Prevention: HPV vaccination (Gardasil, 9-valent) prevents 70–90% of cervical cancers — most effective when given at ages 9–14 before first sexual exposure. Regular Pap smear or HPV co-testing every 3–5 years detects CIN years before invasion — a vaccine-preventable, screenable, curable cancer.
Q133What is robotic surgery for gynaecological cancers?
Robotic surgery is the preferred minimally invasive platform for gynaecological cancer — radical hysterectomy for cervical cancer, total hysterectomy with pelvic lymphadenectomy for endometrial cancer, and staging procedures for early ovarian cancer. Compared to open surgery: less blood loss, hospital stay 1–3 days versus 5–7 days, faster return to normal activities, lower wound complication rate. Compared to standard laparoscopy: 3D magnification and wristed instruments enable safer parametrial dissection, more precise lymphadenectomy, and better vaginal cuff closure. The LACC trial technical modifications — no uterine manipulator, colpotomy bag — are used in Dr. Gore's programme ensuring full oncological equivalence to open surgery.
Q134What is interval debulking surgery (IDS) for ovarian cancer?
IDS is performed after 3 cycles of neoadjuvant platinum-taxane chemotherapy — when primary upfront surgery could not achieve CC-0 or the patient was too frail for primary debulking. The CHORUS and EORTC 55971 trials established IDS as equivalent to primary debulking in overall survival when primary CC-0 is not achievable. HIPEC at IDS (OVHIPEC trial) adds a further 12 months survival benefit. IDS is technically less demanding than primary debulking — neoadjuvant chemotherapy reduces tumour volume making resection safer. The decision between primary debulking and neoadjuvant chemotherapy plus IDS is made at gynaecological oncology MDT based on patient fitness and tumour resectability.
Q135What is fertility preservation in young women with gynaecological cancer?
Fertility-sparing approaches: low-grade endometrial cancer confined to the endometrium — high-dose progestin therapy under close 3-monthly endometrial biopsy surveillance; early cervical cancer (IA2, IB1) — radical trachelectomy removes the cervix while preserving the uterus (pregnancy rates 25–35% at experienced centres); borderline ovarian tumours — cystectomy or unilateral oophorectomy; Stage IA ovarian cancer — careful staging preserving the contralateral ovary and uterus. When fertility-sparing surgery is not oncologically safe, oocyte cryopreservation before chemotherapy is strongly recommended — arranged within 2 weeks of diagnosis through a fertility clinic referral. Fertility implications should be discussed at the very first oncology consultation.
Q136What is pelvic lymph node dissection in cancer surgery?
Pelvic lymph node dissection (PLND) removes obturator, internal iliac, external iliac, and common iliac lymph nodes — for staging and treatment of pelvic cancers. Performed for: radical hysterectomy (always included for cervical cancer); endometrial cancer (for intermediate and high-risk histology); radical cystectomy for bladder cancer (extended PLND improves staging and survival); radical prostatectomy for intermediate and high-risk prostate cancer. Para-aortic lymphadenectomy extends the dissection to nodes along the aorta — used for ovarian, cervical, and endometrial cancers with high para-aortic spread risk. Robotic PLND provides equivalent nodal yield to open surgery with a significantly lower complication rate.
Q137What is CA-125 tumour marker and how is it used?
CA-125 is the most useful tumour marker for ovarian cancer — elevated in 80% of advanced cases and 50% of Stage I disease. Used for: initial assessment of a pelvic mass (combined with transvaginal ultrasound as Risk of Malignancy Index, RMI); monitoring chemotherapy response (falling CA-125 confirms response); and detecting recurrence after completing treatment (rising CA-125 is often the first sign). CA-125 is not specific to ovarian cancer — it can be elevated in endometriosis, fibroids, liver disease, pancreatitis, and even pregnancy — making it unreliable as a screening test in asymptomatic women without a known diagnosis. Always interpret in clinical context.
Q138What is vulval cancer surgery?
Vulval squamous cell carcinoma is treated with wide local excision with 1cm clear margins plus sentinel node biopsy. Sentinel node biopsy for clinically N0 groins avoids routine inguinal node dissection — which carries a 10–15% lymphoedema complication rate. Positive sentinel node requires bilateral inguinal lymph node dissection. Larger tumours with sphincter or anal canal involvement may require radical vulvectomy with perineal reconstruction using a myocutaneous flap. Post-operative radiotherapy is given for positive or close margins and for lymph node-positive disease. HPV is the causal agent in most younger patients. Early-stage vulval cancer (Stage I–II) has excellent prognosis — 5-year survival 80–90% with correct surgical treatment.
Q139What is BRCA mutation and risk-reducing surgery for ovarian cancer?
BRCA1 mutations carry a lifetime ovarian cancer risk of 40–60%; BRCA2 mutations carry 10–20%. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) removes both tubes and ovaries — reducing ovarian and tubal cancer risk by 90–96% in BRCA1 carriers and 95% in BRCA2 carriers when performed before natural menopause. Fallopian tubes are removed first and examined carefully for occult cancer at every RRBSO — most high-grade serous cancers now understood to originate in the fallopian tube fimbria. RRBSO is typically recommended at age 35–40 for BRCA1 and 40–45 for BRCA2 carriers who have completed their families. RRBSO also significantly reduces breast cancer risk in pre-menopausal BRCA1 carriers.
Q140What is staging laparotomy for ovarian cancer?
Staging laparotomy comprehensively stages ovarian cancer — essential because treatment decisions (chemotherapy regimens, radiotherapy, clinical trial eligibility) depend directly on accurate surgical staging. Comprehensive staging includes: systematic inspection of the entire peritoneal cavity; collection of peritoneal washing cytology; multiple peritoneal biopsies; omentectomy; bilateral pelvic and para-aortic lymph node sampling; and removal of all visible tumour deposits (debulking). Minimally invasive staging (laparoscopic or robotic) is appropriate for early-stage (Stage I) ovarian cancer in experienced hands. For advanced disease (Stage III–IV), open staging laparotomy combined with maximal cytoreductive surgery is the standard at specialist ovarian cancer centres with appropriate surgical infrastructure and expertise.
Urological Cancers
Q 141 – 155
Q141What is robotic prostatectomy for prostate cancer?
Robotic radical prostatectomy (RARP) removes the prostate and seminal vesicles for localised prostate cancer — with bilateral nerve-sparing technique preserving the neurovascular bundles responsible for erectile function. The 10x 3D view enables precise identification of nerves and the urethral sphincter controlling continence. Bilateral nerve-sparing RARP achieves continence recovery in 85–95% and erectile function recovery in 60–80% of appropriately selected younger patients. Pelvic lymph node dissection is performed for intermediate and high-risk disease. Post-operative PSA monitoring starts at 6 weeks — an undetectable PSA confirms complete prostate removal. Full robotic programme including prostatectomy details at bestroboticsurgeonpune.in.
Q142What is partial versus radical nephrectomy for kidney cancer?
Partial nephrectomy removes the tumour with a margin of normal kidney — preserving remaining function. It is the preferred approach for tumours under 4cm (T1a) and increasingly for tumours up to 7cm when technically feasible. Preserving kidney function has long-term benefits beyond cancer — preventing chronic kidney disease and reducing cardiovascular risk. Radical nephrectomy removes the entire kidney — preferred for large tumours above 7cm, centrally located tumours not amenable to partial resection, or tumours with renal vein extension. Both procedures are performed laparoscopically or robotically. Robotic partial nephrectomy minimises warm ischaemia time (kidney clamping during tumour resection) through precise, rapid dissection under 3D magnification.
Q143What are the signs and symptoms of bladder cancer?
Bladder cancer most commonly presents with painless haematuria — blood in the urine visible as pink, red, or cola-coloured discolouration. Painless haematuria distinguishes bladder cancer from the painful haematuria of urinary infection or stones. Less commonly: irritative bladder symptoms (frequency, urgency, dysuria) mimicking urinary infection; passage of blood clots; and pelvic pain in advanced disease. Any macroscopic haematuria in an adult requires urgent cystoscopy regardless of other apparent explanations — never attributed to urinary infection alone without endoscopic investigation. Risk factors: smoking is the strongest modifiable risk factor, doubling bladder cancer risk; aromatic amine occupational exposure; and chronic cystitis.
Q144What is radical cystectomy for bladder cancer?
Radical cystectomy removes the entire bladder for muscle-invasive bladder cancer (Stage T2+). In men: prostate and seminal vesicles are also removed. In women: uterus, ovaries, and anterior vaginal wall are removed. Extended pelvic lymph node dissection is performed in all cases. Urinary reconstruction: neobladder — fashioned from ileum, anastomosed to urethra, allowing normal voiding; or ileal conduit — urostomy stoma. Robotic radical cystectomy (RARC) with intracorporeal diversion is performed at specialist centres. Neoadjuvant gemcitabine plus cisplatin chemotherapy before radical cystectomy significantly improves overall survival and should be offered to all fit patients with muscle-invasive bladder cancer.
Q145What is a PSA test and what level requires further investigation?
PSA (Prostate Specific Antigen) blood test screens for prostate cancer and monitors response after treatment. PSA above 4.0 ng/mL warrants urology referral; PSA above 10 ng/mL carries approximately 50% cancer probability. PSA velocity — a rapidly rising PSA above 0.75 ng/mL per year — is more concerning than a stable elevated level. PSA can be elevated by benign causes — urinary infection, prostatitis, recent instrumentation, ejaculation, and benign prostatic hyperplasia — making clinical context essential. MRI prostate before biopsy (mpMRI) dramatically improves cancer detection accuracy — replacing random biopsy with targeted biopsy of suspicious lesions. All PSA results should be interpreted in full clinical context with an experienced urologist or uro-oncologist.
Q146What is TURBT for bladder cancer?
TURBT (Transurethral Resection of Bladder Tumour) removes superficial bladder cancer endoscopically through a resectoscope passed via the urethra. TURBT serves both diagnostic and therapeutic purposes. The critical requirement: deep resection must include detrusor muscle in the specimen — to determine whether the tumour invades muscle (MIBC, requiring cystectomy) or is confined to mucosa and submucosa (NMIBC, treated with TURBT plus intravesical BCG). Second-look TURBT at 4–6 weeks is recommended for high-grade NMIBC to confirm complete resection. BCG intravesical immunotherapy prevents recurrence and progression in high-grade NMIBC — the most effective non-surgical treatment for non-muscle-invasive bladder cancer.
Q147What is the survival rate for prostate cancer?
Prostate cancer survival depends on risk category at diagnosis. Localised disease (all risk groups): 5-year survival approaches 100% with surgery, radiotherapy, or active surveillance. Locally advanced (T3-T4): 85–90% with multimodal treatment. Metastatic hormone-sensitive prostate cancer: median overall survival exceeds 4–5 years with ADT plus docetaxel, or ADT plus enzalutamide or abiraterone. Castration-resistant metastatic prostate cancer: median survival 2–3 years with sequential systemic therapies. BRCA2 mutations occur in 10–12% of metastatic prostate cancer — these patients respond to PARP inhibitors (olaparib, rucaparib). Germline genetic testing is recommended for all metastatic prostate cancer patients.
Q148What is neobladder reconstruction after radical cystectomy?
Neobladder is a urinary reservoir fashioned from 40–60cm of ileum — anastomosed to the urethra after cystectomy — allowing voiding per urethra instead of through a stoma. The neobladder fills by gravity and empties by abdominal straining and Valsalva manoeuvre. Advantages: no external stoma, improved body image. Requirements: intact functional urethra; motivated patient capable of self-catheterisation if retention develops; adequate renal function. Disadvantages: lifelong metabolic monitoring (bowel mucosa absorbs ammonium — risk of metabolic acidosis); night-time leakage initially; higher early complication rate than ileal conduit. Patient selection requires specialist counselling discussing all urinary diversion options honestly before cystectomy.
Q149What is testicular cancer treatment?
Testicular germ cell tumours are the most common solid malignancy in men aged 15–40 — and one of the most curable. First treatment: radical orchidectomy via inguinal incision — never transscrotal. Staging: CT chest/abdomen/pelvis plus markers (AFP, HCG, LDH). Stage I (confined to testis): surveillance or single carboplatin cycle (seminoma); surveillance or BEP times 1 cycle (NSGCT). Stage II–III: BEP chemotherapy (bleomycin, etoposide, cisplatin). Retroperitoneal lymph node dissection (RPLND) for Stage II NSGCT with residual masses after chemotherapy. Five-year survival: Stage I greater than 99%; Stage III disseminated disease 60–80% — exceptional outcomes for metastatic solid cancer with correct treatment.
Q150What is renal cell carcinoma and how is it treated?
RCC arises from renal tubular cells — clear cell (70–75%), papillary (10–15%), chromophobe (5%) subtypes. Surgery is curative for localised RCC — partial nephrectomy preferred for tumours under 7cm; radical nephrectomy for larger or central tumours. Metastatic RCC: first-line combination immunotherapy (nivolumab plus ipilimumab, or pembrolizumab plus axitinib) has transformed outcomes — median overall survival now exceeds 3–4 years in favourable-risk disease. Cytoreductive nephrectomy for selected patients with good performance status and limited metastatic disease may improve immunotherapy response. Adjuvant pembrolizumab reduces recurrence after nephrectomy for high-risk localised RCC (KEYNOTE-564 trial). Genetic testing recommended for bilateral, multifocal, or young-onset RCC.
Q151What is active surveillance for prostate cancer?
Active surveillance (AS) monitors very low and low-risk localised prostate cancer without immediate treatment — deferring surgery or radiotherapy and intervening only if the cancer shows progression. It avoids treatment side effects (incontinence, erectile dysfunction) in patients whose cancer is unlikely to cause harm in their lifetime. Eligibility: PSA under 10, Gleason grade group 1, T1c/T2a, 2 or fewer positive cores with less than 50% core involvement. AS protocol: PSA every 3–6 months; mpMRI annually; repeat biopsy at 1 year and then every 2–3 years. The ProtecT trial confirmed AS has equivalent 10-year cancer-specific survival to immediate radical treatment for low-risk disease. 40–50% of AS patients eventually require active treatment.
Q152What is BCG therapy for bladder cancer?
BCG (Bacillus Calmette-Guérin) intravesical immunotherapy is the most effective treatment for high-risk non-muscle-invasive bladder cancer (NMIBC). BCG activates macrophages, T cells, and NK cells within the bladder urothelium — stimulating anti-tumour immunity. Protocol: weekly instillations for 6 weeks (induction), then monthly maintenance for up to 3 years (full SWOG maintenance). Response rates: 70–80% complete response for high-grade Ta/T1 tumours. BCG intolerance (burning, frequency, rarely BCG sepsis) occurs in 20–30% of patients — dose reduction, antibiotics, or switch to intravesical mitomycin C may be required. BCG failure — persistent high-grade tumour after adequate BCG therapy — is an indication for radical cystectomy.
Q153What is adrenal gland surgery for cancer?
Adrenal tumours requiring surgery: adrenocortical carcinoma (rare, aggressive — en bloc resection with adjacent kidney and lymph nodes; adjuvant mitotane); phaeochromocytoma (catecholamine-secreting — critical: alpha-blockade with phenoxybenzamine for 10–14 days before surgery to prevent hypertensive crisis during anaesthesia); adrenal metastases from lung, renal, or breast cancer; and large non-functioning adenomas above 4cm. Surgery: laparoscopic or robotic adrenalectomy for most tumours under 6cm; open surgery for adrenocortical carcinoma requiring wider margins. Pre-operative functional assessment (urinary catecholamines, dexamethasone suppression test) is mandatory before any adrenal surgery — every incidentaloma must be tested for hormonal activity.
Q154What is Wilms tumour in children?
Wilms tumour (nephroblastoma) is the most common renal malignancy in children — usually presenting at ages 3–5 as an abdominal mass. SIOP protocol: preoperative chemotherapy (actinomycin D plus vincristine for localised disease) for 4–6 weeks before nephrectomy — reducing surgical complications and tumour size significantly. Surgery: radical nephrectomy with regional lymph node sampling. Post-operative chemotherapy intensity depends on histological risk (favourable versus blastemal-type) and stage. Overall cure rate exceeds 85–90% with modern treatment. Bilateral Wilms tumours (5% of cases) require nephron-sparing surgery to preserve kidney function. WT1 gene mutations are common — genetic counselling is recommended when bilateral disease or associated anomalies are present.
Q155What is penile cancer surgery?
Penile squamous cell carcinoma is treated with organ-preserving surgery whenever oncologically safe: glansectomy with skin graft reconstruction; wide local excision for small superficial lesions; partial penectomy when preservation cannot achieve clear margins. Inguinal lymph node management is critical — dynamic sentinel node biopsy for clinically N0 groins in T1 Grade 2 or higher tumours. Positive sentinel node requires bilateral inguinal lymph node dissection. Inguinal dissection carries a 10–15% lymphoedema complication rate — ICG fluorescence sentinel node mapping reduces unnecessary dissection. Early-stage penile cancer (Stage I–II) has excellent prognosis — 5-year survival 80–90% with correct surgical treatment. HPV vaccination prevents the majority of penile squamous cell carcinomas.
Thoracic Cancer Surgery
Q 156 – 165
Q156What is lung cancer surgery and who is eligible?
Lung cancer surgery — primarily for non-small cell lung cancer (NSCLC: adenocarcinoma, squamous cell carcinoma) — is curative treatment for Stage I and II, and selected Stage IIIA disease. Eligibility requires: adequate pulmonary function (FEV1 and DLCO above thresholds); good cardiovascular fitness; no mediastinal nodal involvement (N2/N3 generally excludes surgery); and no systemic metastases on PET-CT. Preoperative assessment: spirometry, DLCO, echocardiogram, CT chest/abdomen/pelvis, PET-CT, and EBUS for mediastinal node sampling. Stage I NSCLC surgery achieves 5-year survival of 60–80%. Adjuvant osimertinib is standard for EGFR-mutant Stage IB–IIIA after resection; cisplatin plus vinorelbine for Stage II non-mutant disease.
Q157What is VATS lobectomy for lung cancer?
VATS (Video-Assisted Thoracoscopic Surgery) lobectomy removes a lobe of lung through 2–4 small port incisions and a 3–5cm utility incision — without rib spreading. Multiple large RCTs confirm equivalent oncological outcomes to open thoracotomy — equivalent R0 rates, lymph node harvest, and 5-year survival — with dramatically better recovery: shorter chest drain duration (1–3 days vs 3–5 days), shorter hospital stay (3–5 vs 5–8 days), less pain, lower pulmonary complication rate, and lower atrial fibrillation rate. VATS lobectomy has replaced open thoracotomy as the standard for peripheral Stage I–II NSCLC at specialist thoracic centres. Robotic lobectomy extends these benefits with 3D vision and wristed instruments.
Q158What are the warning signs of lung cancer?
Signs requiring urgent investigation: persistent cough lasting more than 3 weeks — particularly a new or changed cough in a current or former smoker; haemoptysis (coughing blood in any amount); breathlessness disproportionate to exertion; wheeze or stridor suggesting endobronchial tumour; recurrent pneumonia in the same area of the lung; significant unexplained weight loss; bone pain suggesting metastases; hoarseness from left recurrent laryngeal nerve involvement by mediastinal tumour; and Pancoast syndrome — shoulder and arm pain from an apex tumour invading the brachial plexus. Any persistent respiratory symptom in a current or former smoker requires urgent chest X-ray and CT chest.
Q159What is the CROSS protocol for oesophageal cancer?
CROSS — ChemoRadiation for Oesophageal cancer followed by Surgery Study (NEJM 2012) — is the established neoadjuvant treatment regimen for resectable oesophageal cancer. Protocol: weekly carboplatin plus paclitaxel for 5 cycles concurrent with 41.4 Gy radiotherapy in 23 fractions. Results: pathological complete response in 49% of squamous cell carcinoma and 23% of adenocarcinoma; overall survival improved from 24 to 49 months versus surgery alone. CROSS is now the international standard pre-operative treatment before esophagectomy for Stage II–III oesophageal cancer. Post-CROSS esophagectomy — performed by RAMIE at Sahyadri Manipal Hospital — provides definitive surgical resection with pathological response assessment.
Q160What is thymoma and thymectomy?
Thymoma is the most common primary mediastinal tumour in adults — presenting as an anterior mediastinal mass, often incidentally discovered. Importantly, 30–40% of thymoma patients have associated myasthenia gravis (MG) — an autoimmune neuromuscular condition causing fatigable muscle weakness. Thymectomy (removal of the thymus) treats both the thymoma and improves MG outcomes — the randomised MGTX trial confirmed thymectomy benefit in myasthenia. Approach: VATS thymectomy is standard for Stage I–II thymoma; sternotomy for larger or Stage III disease. WHO classification (Type A through B3 and thymic carcinoma) predicts biological behaviour — Type A has excellent prognosis; thymic carcinoma is aggressive requiring multimodal treatment.
Q161What is stereotactic body radiotherapy (SBRT) for lung cancer?
SBRT (or SABR — Stereotactic Ablative Radiotherapy) delivers highly concentrated, precisely targeted radiation to early-stage lung tumours in 3–8 sessions — without surgery. Used for Stage I NSCLC in patients who are medically inoperable (inadequate lung function, cardiac comorbidity) or who decline surgery. SBRT achieves local control rates of 85–95% for Stage I tumours — comparable to surgery in direct comparisons. Not suitable for central tumours close to major airways. For patients with Stage I NSCLC who are surgically borderline, the decision between SBRT and VATS lobectomy is best made at a thoracic MDT where both thoracic surgeon and radiation oncologist provide input for a balanced, objective recommendation.
Q162What is the recovery after VATS thoracoscopic lung surgery?
Recovery after VATS lobectomy: chest drain removed day 2–3 when output is low and air leak has resolved; hospital stay 3–5 days. Shoulder tip pain and port site discomfort managed with regular paracetamol, NSAIDs, and intercostal nerve block given at surgery. Pulmonary physiotherapy — deep breathing exercises, incentive spirometry, and early mobilisation — begins within hours of surgery. Activities: walking from day 1; avoid lifting more than 5kg for 4 weeks; driving resumes after 2–3 weeks when shoulder pain resolves. Return to desk work: 3–4 weeks; physical roles: 6–8 weeks. Adjuvant chemotherapy or targeted therapy (osimertinib) starts 4–6 weeks after surgery once wound healing is confirmed.
Q163What is mesothelioma and how is it treated?
Pleural mesothelioma is a cancer of the pleural lining — strongly associated with asbestos exposure with a latency of 30–50 years. Presents with breathlessness, pleuritic chest pain, and unilateral pleural effusion. Diagnosis requires pleural biopsy with IHC (calretinin, WT1 positive; CEA, TTF-1 negative). Treatment: chemotherapy (cisplatin plus pemetrexed as standard first-line); immunotherapy (nivolumab plus ipilimumab — FDA-approved for all histological subtypes); surgery in selected young fit patients — extended pleurectomy/decortication (eP/D) preferred over extrapleural pneumonectomy. Prognosis is poor — median survival 12–18 months — but improving with immunotherapy combinations. Asbestos exposure history should always be specifically documented.
Q164What is mediastinoscopy and when is it needed in lung cancer?
Mediastinoscopy samples lymph nodes in the mediastinum through a small cervical incision — used to confirm or exclude N2/N3 mediastinal nodal involvement in lung cancer staging. This distinction is critical — N2/N3 disease (Stage IIIA/B) means primary chemoradiation rather than surgery in most cases. EBUS (Endobronchial Ultrasound) — flexible bronchoscope with real-time ultrasound allowing FNA of mediastinal nodes — has largely replaced mediastinoscopy as the first-line staging tool. Mediastinoscopy is now used when EBUS is non-diagnostic or when tissue confirmation is needed before surgery in equivocal cases. The N0/N1 versus N2/N3 distinction is one of the most clinically consequential staging decisions in thoracic oncology.
Q165What is segmentectomy for early lung cancer?
Segmentectomy removes a specific bronchopulmonary segment — less lung than a full lobectomy — for small peripheral Stage IA tumours. Two landmark RCTs (JCOG 0802 and LCSG-821) established that anatomical segmentectomy is non-inferior to lobectomy for peripheral Stage IA tumours under 2cm — particularly those showing ground-glass opacity (GGO) on CT. The key benefit: better preservation of pulmonary function — important for patients with limited respiratory reserve who need every functional lung unit preserved. Wedge resection (non-anatomical) carries higher local recurrence rates than anatomical segmentectomy. Robotic segmentectomy uses ICG fluorescence for precise segment boundary identification — the most technically demanding thoracoscopic approach.
⚡
Electrochemotherapy (ECT)
Q 166 – 175
Q166What is electrochemotherapy (ECT) and how was it pioneered in Asia?
ECT combines a standard chemotherapy drug — most commonly bleomycin — with precisely timed short electrical pulses delivered directly to the tumour. The pulses reversibly open cancer cell membranes through electroporation — creating temporary nanopores allowing 100–700 times more chemotherapy to enter the cell than systemic administration achieves. Developed at Institut Gustave Roussy, France in the early 1990s and standardised through the European ESOPE trial (2006). Dr. Vinod T. Gore pioneered ECT in Asia in 2013 at Sahyadri Manipal Hospital, Pune — one of the first practitioners in the region and a clinical leader in its application for Asian cancer patients. ECT is available at Sahyadri Manipal Hospital Pune. Call 88558 10010.
Q167How does electrochemotherapy work at the cellular level?
ECT exploits bleomycin's inherent limitation — it is highly cytotoxic but crosses cell membranes poorly, limiting intracellular accumulation after systemic dosing. Short (100 microsecond), high-voltage electrical pulses applied through electrode applicators around the tumour transiently disrupt the phospholipid bilayer of cell membranes — creating temporary nanopores. During this brief permeabilisation window lasting seconds to minutes, the surrounding bleomycin enters the cell at dramatically higher concentrations. Inside the cell, bleomycin induces double-strand DNA breaks triggering programmed cell death (apoptosis). Surrounding normal tissue is minimally affected — because the electrical field is localised to the applicator region and normal cells are not intrinsically damaged by bleomycin at pharmacological concentrations.
Q168What cancers and tumour types are treated with ECT?
ECT is most effective for superficial and accessible tumour nodules: breast cancer chest wall recurrence — one of the most common indications achieving complete response in 70–80% of treated lesions; cutaneous and subcutaneous metastases from any primary (melanoma, colorectal, ovarian, sarcoma, lymphoma); head and neck tumours — unresectable or recurrent oral, skin, and neck deposits; Kaposi's sarcoma; malignant melanoma nodular or satellite lesions; primary skin cancers (BCC, SCC, Merkel cell carcinoma); lymph node deposits accessible by surface or interstitial electrode; and soft tissue deposits on the chest wall or abdominal wall. Best results for nodules under 3cm in diameter. Not suitable for diffuse peritoneal disease.
Q169What are the advantages of ECT over conventional treatment for skin and soft tissue tumours?
ECT offers important advantages for superficial and recurrent tumour nodules: complete response in 60–80% of treated lesions in published series — for deposits that have failed surgery, radiotherapy, and systemic chemotherapy; minimal systemic toxicity — bleomycin delivered at a fraction of the conventional dose; multiple lesions treated in a single session; no significant scarring in most cases; repeatable for new or residual deposits; effective irrespective of prior chemotherapy resistance (electroporation bypasses membrane transport resistance mechanisms); suitable for patients unfit for major surgery or who have exhausted systemic options; and day-case or brief admission in most cases. ECT complements curative surgery — it does not replace it when resection is oncologically feasible.
Q170What drugs are used in ECT and how are they administered?
Two agents are used in ECT protocols. Bleomycin — the standard: given IV bolus (15,000 IU/m² over 30 minutes) with electrical pulses delivered 8–28 minutes later at peak plasma concentration; or intralesional injection (1000 IU per cm³ tumour) with pulses delivered 1 minute later. IV bleomycin treats multiple lesions simultaneously. Cisplatin — used intralesionally for specific tumour types or when bleomycin is less effective. The electrical pulse is delivered by the clinically validated Cliniporator device (IGEA, Italy) using surface electrode plates for superficial lesions or needle electrode arrays for deeper deposits. General anaesthesia or deep IV sedation is standard — making ECT a comfortable day-case procedure for the patient.
Q171What happens on the day of ECT treatment?
ECT is performed under general anaesthesia or deep IV sedation. On the day: IV cannulation; full blood count and coagulation check; bleomycin administered IV 8–28 minutes before electrical pulses or intralesionally immediately before pulses; electrode applicator positioned around or into the tumour; 8 sequences of 100-microsecond pulses delivered — the treatment takes seconds to minutes per lesion; multiple nodules treated sequentially in the same session. Post-procedure observation for 2–4 hours; mild analgesics for discomfort; treated lesions become red and oedematous acutely — this resolves over days. Most patients go home the same day. Response assessment by clinical measurement and photography at 4–8 weeks determines whether repeat treatment is needed.
Q172What is the expected response rate from electrochemotherapy?
From the ESOPE trial and subsequent published series: complete response (CR — complete disappearance of treated lesion) in 59–84% of lesions depending on tumour type; partial response (greater than 50% reduction) in a further 10–20%; objective response rate 85–95% for selected tumour types. Best results: breast cancer chest wall deposits (CR 70–80%); non-melanoma skin cancers; head and neck deposits. Melanoma nodules: CR 50–60%. Factors predicting better response: smaller lesions under 1cm; non-melanoma histology; adequate electrode coverage of the entire lesion. Lesions above 3cm have lower CR rates. Repeat ECT sessions for residual or new lesions are feasible and well-tolerated with equivalent response rates.
Q173What are the side effects of electrochemotherapy?
ECT has a favourable side effect profile. Local effects: treated area becomes red, swollen, and oedematous for 24–72 hours; the lesion may form a crust or eschar over 2–4 weeks as tumour cells are cleared; mild discomfort at the treated site for 3–7 days managed with simple oral analgesia. Bleomycin systemic effects at ECT doses (far below conventional therapeutic doses): very mild nausea lasting 24 hours; alopecia does not occur; no significant bone marrow suppression at these doses. Critical contraindication: prior cumulative bleomycin approaching 400,000 IU total lifetime dose — risk of pulmonary fibrosis. ECG check before ECT for cardiac patients — pulse timing is adjusted to the cardiac R-wave to prevent any arrhythmia risk during treatment.
Q174Can ECT treat breast cancer chest wall recurrence?
Breast cancer chest wall recurrence — cancer returning as nodules on the skin or chest wall after mastectomy — is one of the most common and most rewarding ECT indications. The area is often heavily irradiated (limiting further radiotherapy), and surgical excision of multiple nodules in scarred skin is technically demanding with high wound complication rates. ECT treats multiple nodules in a single session regardless of their number or exact location — with complete response rates of 70–80% per individual lesion. Sequential ECT sessions treat new nodules as they appear over months. ECT can be combined with concurrent systemic treatment (hormonal therapy, anti-HER2, chemotherapy) without contraindication — the local ECT effect is independent of systemic drug resistance.
Q175Is electrochemotherapy available in India?
Yes. Dr. Vinod T. Gore pioneered ECT in Asia in 2013 — one of the first practitioners in the region. ECT is available at Sahyadri Manipal Hospital, Hadapsar, Pune using the clinically validated Cliniporator device (IGEA, Italy). The programme treats chest wall recurrence of breast cancer, melanoma nodules, head and neck deposits, soft tissue lesions, and other accessible tumour nodules not suitable for conventional surgery or radiotherapy. For ECT consultation at Silver Leaf Clinic, Hadapsar: call 88558 10010 or WhatsApp 84118 08284. Bring clinical photographs of all lesions, previous treatment records including any prior bleomycin cumulative dose, and imaging of the treatment area to your first ECT consultation.
🦴
Sarcoma & Rare Cancers
Q 176 – 185
Q176What is soft tissue sarcoma and how is it treated?
Soft tissue sarcoma (STS) is a heterogeneous group of malignant tumours from mesenchymal tissues — fat (liposarcoma), smooth muscle (leiomyosarcoma), vessels (angiosarcoma), fibrous tissue (fibrosarcoma) — comprising over 50 histological subtypes. Surgery with wide margins (R0, 1–2cm) is the cornerstone of curative treatment. Limb-sparing surgery combined with radiotherapy preserves the limb in 95% of cases — amputation is now required in fewer than 5%. Neoadjuvant radiotherapy reduces local recurrence for large (above 5cm) high-grade limb tumours. Adjuvant chemotherapy (doxorubicin plus ifosfamide) is reserved for young patients with large high-grade tumours at high metastatic risk. Specialist sarcoma MDT review is essential — surgeon volume and institutional expertise directly impact outcomes for these rare tumours.
Q177What is limb salvage surgery for bone tumours?
Limb salvage surgery removes the bone tumour while preserving the limb — replacing the resected segment with a metallic endoprosthesis, allograft bone, or combination. LSS achieves equivalent survival to amputation and is now standard for most primary bone tumours including osteosarcoma, Ewing sarcoma, and chondrosarcoma. Amputation is required in fewer than 5% of bone cancer cases with current techniques. Neoadjuvant chemotherapy before surgery: MAP protocol (methotrexate, doxorubicin, cisplatin) for osteosarcoma; VIDE for Ewing sarcoma. Pathological response after neoadjuvant chemotherapy — necrosis above 90% — is the strongest prognostic factor for long-term survival after limb salvage surgery. Intensive rehabilitation begins within days of the operation.
Q178What is malignant melanoma surgery?
Melanoma surgery has three components. Primary excision: wide local excision with margin determined by Breslow thickness — under 1mm: 1cm margin; 1–2mm: 1–2cm margin; above 2mm: 2cm margin. Sentinel node biopsy: for Breslow thickness above 0.8mm or any thickness with ulceration or mitoses — identifies nodal spread upstaging the patient. Positive sentinel node: completion lymph node dissection or surveillance with ultrasound (MSLT-II trial showed equivalent outcomes). Adjuvant therapy for Stage III–IV: anti-PD-1 immunotherapy (pembrolizumab or nivolumab) or BRAF/MEK targeted therapy (dabrafenib plus trametinib) for BRAF V600E mutant tumours. BRAF mutation testing is mandatory for all Stage III/IV melanoma patients before treatment planning.
Q179What is retroperitoneal sarcoma surgery?
Retroperitoneal sarcomas — most commonly well-differentiated liposarcoma (WDLPS) and leiomyosarcoma — present as large asymptomatic abdominal masses. Surgery is the only potentially curative treatment: en bloc multivisceral resection removing all attached organs (almost always including the ipsilateral kidney and adrenal) with the tumour as one intact specimen — never shelling out the tumour along its pseudo-capsule. Local recurrence is the primary mode of failure — 5-year local recurrence 30–60% even after R0 resection for WDLPS. Preoperative radiotherapy may reduce local recurrence in selected patients. Referral to a specialist sarcoma centre with dedicated retroperitoneal surgical expertise and infrastructure is essential for optimal surgical and oncological outcomes.
Q180What is GIST and imatinib targeted therapy?
GIST (Gastrointestinal Stromal Tumour) is driven by constitutively activated KIT or PDGFRA tyrosine kinase mutations. Imatinib (Gleevec) is a targeted TKI blocking the mutated KIT signalling pathway — achieving response in over 80% of KIT exon 11 GIST patients. Before imatinib: median metastatic GIST survival was under 2 years. With imatinib: many metastatic patients now live 5–10 years. Adjuvant imatinib for 3 years reduces recurrence by 50–60% in high-risk resected GIST (SSGXVIII trial). PDGFRA D842V mutation is imatinib-resistant — requires avapritinib (Ayvakit). KIT and PDGFRA molecular mutation testing is mandatory before starting any systemic therapy for GIST — the mutation type determines which drug is appropriate.
Q181What is carcinoid syndrome and how is it managed?
Carcinoid syndrome — flushing, explosive watery diarrhoea, bronchospasm, and right-sided cardiac disease — is caused by serotonin secretion from NET liver metastases bypassing hepatic inactivation through the portal circulation. Only 10% of NETs cause carcinoid syndrome. Treatment: octreotide LAR (Sandostatin LAR 30mg monthly) controls symptoms in 70% of patients; telotristat ethanolamine for refractory diarrhoea. Carcinoid crisis — a life-threatening haemodynamic emergency triggered by anaesthesia — is prevented by octreotide infusion starting 12 hours before any surgery in functional NET patients. 24-hour urinary 5-HIAA and serum chromogranin A (CgA) are the diagnostic and long-term monitoring markers for carcinoid tumours.
Q182What is PRRT therapy for neuroendocrine tumours?
PRRT — Peptide Receptor Radionuclide Therapy — using Lu-177 DOTATATE (Lutathera) delivers targeted radiotherapy to somatostatin receptor-expressing NETs administered intravenously. The DOTATATE peptide homes to somatostatin receptors on NETs, delivering Lu-177 radioactive payload precisely to tumour cells while sparing surrounding normal tissue. The NETTER-1 trial (NEJM 2017): 65% reduction in PFS events and 79% disease control rate versus high-dose octreotide in progressive midgut NETs. Given in 4 cycles, 8 weeks apart. Eligibility: positive Ga-68 DOTATATE PET-CT confirming adequate receptor expression; well-differentiated G1/G2 NET; adequate renal function. Amino acid infusion is co-administered for renal protection during each cycle.
Q183What is Merkel cell carcinoma treatment?
Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine skin cancer presenting as a rapidly growing flesh-coloured or bluish nodule on sun-exposed areas in elderly patients. Linked to Merkel cell polyomavirus (MCPyV) in 80% of cases. Surgery: wide local excision with 1–2cm margins plus sentinel node biopsy — nodal involvement found in 30–40% of clinically N0 patients and is the most important prognostic factor. Post-operative radiotherapy to the primary site and draining lymph nodes significantly reduces local recurrence. Metastatic MCC: immunotherapy with avelumab (FDA-approved) or pembrolizumab achieves durable responses in 30–40% of patients — remarkable for Stage IV disease. MCPyV-positive tumours respond better to immunotherapy than MCPyV-negative tumours.
Q184What is dermatofibrosarcoma protuberans (DFSP)?
DFSP is a low-grade fibroblastic skin tumour — most common on the trunk and proximal extremities — characterised by infiltrative growth along fascial planes making complete excision technically demanding. Standard treatment: wide local excision with 2–3cm margins; Mohs micrographic surgery (staged excision with margin mapping by frozen section) achieves local recurrence rates below 5%. DFSP is driven by COL1A1-PDGFRB gene translocation — sensitive to imatinib, which achieves response in 60–70% of locally advanced or metastatic cases. Neoadjuvant imatinib shrinks unresectable DFSP to enable subsequent surgical resection. Fibrosarcomatous transformation of DFSP carries metastatic risk and requires adjuvant chemotherapy consideration at a specialist sarcoma MDT.
Q185What is neuroendocrine carcinoma (NEC) and how is it different from NET?
Neuroendocrine carcinoma (NEC) is poorly differentiated — Ki-67 above 20%, resembling small cell carcinoma biologically. NEC is fundamentally different from well-differentiated neuroendocrine tumour (NET, Ki-67 under 20%) in biology, treatment, and prognosis. NEC is treated with platinum-based chemotherapy (cisplatin or carboplatin plus etoposide) — similar to small cell lung cancer — not with SSA or PRRT. Somatostatin receptor expression is usually absent or low in NEC making SSA and PRRT ineffective. Surgery plays a limited role in NEC due to aggressive biology and frequent early systemic spread. Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) require expert pathological review at a specialist NET centre — the treatment approach follows the more aggressive component.
Dr. Gore & Silver Leaf Clinic — Contact & Information
Q 186 – 200
Q186Who is Dr. Vinod T. Gore and what are his qualifications?
Dr. Vinod T. Gore is one of India's most senior surgical oncologists — 30+ years dedicated exclusively to cancer surgery. Qualifications: MBBS (ranked 2nd, University of Pune); MS General Surgery (ranked 2nd); FAIS (Fellow, Association of Indian Surgeons); FIAGES (Fellow, Indian Association of GI Endosurgeons); FARIS — Fellow in Advanced Robotic and Innovative Surgery, University of Edinburgh; DNB Guide. Training: 5-year Surgical Oncology residency at Tata Memorial Hospital Mumbai; 3 years plastic and reconstructive surgery at Sassoon General Hospital Pune; Research Fellowship in Thoracic Oncology, Tata Memorial Hospital. Positions: Department Head Surgical Oncology, Sahyadri Manipal Hospital (since 2009); Owner, Silver Leaf Clinic Hadapsar; former Associate Professor of Surgery, Bharati Vidyapeeth Medical College (11 years). MMC Registration: 90942.
Q187What awards has Dr. Gore received?
Dr. Gore has received three notable recognitions: Trailblazer Leaders in Oncology — Economic Times Onco Frontiers Meet 2025 — his primary award, recognising pioneering contributions to surgical oncology in India; Best Robotic Oncosurgeon — Navbharat Times 2024 — acknowledging leadership in robotic cancer surgery in Pune; and Asia Pioneer of Electrochemotherapy — introducing ECT to Asia in 2013 at Sahyadri Manipal Hospital, a landmark advance in regional cancer surgery. Academic distinctions: Dr. Jejurkar Award; ranked 2nd in both MBBS and MS at University of Pune. Organising Secretary: MOGCON 2018, ICON 2023, Best of ASCO 2024 — demonstrating sustained active academic leadership in surgical oncology.
Q188Where is Silver Leaf Clinic Hadapsar and how do I get there?
Silver Leaf Clinic is at 511, City Centre, Solapur Road, Opposite Vaibhav Theatre, Hadapsar, Pune 411028 — conveniently accessible from Hadapsar, Fatima Nagar, Kharadi, Magarpatta City, and the Pune-Solapur highway. Google Maps: search 'Dr Vinod Gore Silver Leaf Clinic' for turn-by-turn directions. OPD hours: Monday to Saturday, 10:00 AM to 6:00 PM. Sunday: by prior appointment only. All cancer surgery consultations, second opinions, and post-operative follow-up are at Silver Leaf Clinic. Major operations at Sahyadri Manipal Hospital, Hadapsar — the designated Robotic Cancer Surgery Centre of Excellence. Call 88558 10010 to book your consultation.
Q189What is the phone number of Silver Leaf Clinic Pune?
Silver Leaf Clinic OPD: 88558 10010 — for appointment booking, consultation queries, and general clinic information. Silver Leaf Clinic Landline: +91 20 6768 9704. Dr. Gore Direct and WhatsApp: 84118 08284 — for outstation patients, sharing of imaging and reports via WhatsApp before travelling to Pune, urgent clinical queries, and video consultation scheduling. Outstation and international patients can share CT scans, MRI, PET-CT images, and biopsy reports via WhatsApp for preliminary review before the appointment. Video consultation is available for second opinion and pre-operative planning. Address: 511 City Centre, Solapur Road, Hadapsar, Pune 411028.
Q190How to book an appointment with Dr. Gore for cancer surgery?
To book a consultation at Silver Leaf Clinic, Hadapsar, Pune: call 88558 10010 (Silver Leaf Clinic OPD) or WhatsApp 84118 08284 (Dr. Gore Direct). Consultations available Monday to Saturday, 10:00 AM to 6:00 PM. For a cancer surgery consultation bring: CT/MRI/PET-CT scans on CD or share via WhatsApp; all biopsy and pathology reports with full IHC panel; blood investigations; previous operative notes if applicable; and any chemotherapy or radiotherapy treatment summaries including drug names and cycles completed. Outstation patients can arrange a preliminary video consultation before travelling. Urgent oncological cases are prioritised — same-day or next-day appointments can be arranged when necessary.
Q191What cancers does Dr. Gore specialise in treating?
Dr. Gore's surgical oncology practice covers all major cancer types: colorectal cancer — robotic TME, LAR, APR; upper GI cancer — oesophageal and gastric robotic surgery; HPB cancers — Whipple, hepatectomy, CRLM; breast cancer — oncoplastic, mastectomy, reconstruction; thyroid and parathyroid cancer; head and neck cancer — oral, salivary gland, laryngeal, neck dissection; gynaecological cancers — radical hysterectomy, ovarian debulking; urological cancers — prostatectomy, nephrectomy, cystectomy; thoracic cancer; GIST and neuroendocrine tumours; soft tissue sarcoma; HIPEC for peritoneal disease; electrochemotherapy; and ICG fluorescence surgery across all organ systems. Sister specialist sites: bestbreastsurgeon.in · bestthyroidsurgeon.in · bestroboticsurgeonpune.in · cancerclinicpune.com.
Q192Where does Dr. Gore perform all major cancer surgery?
All major cancer operations — robotic surgery, HIPEC, open complex cancer surgery, and thoracic surgery — are performed at Sahyadri Manipal Hospital, Hadapsar, Pune. This hospital is the designated Robotic Cancer Surgery Centre of Excellence, ARIS accredited, with the full technical infrastructure for complex operations: da Vinci Xi robotic system, dedicated ICU, specialist oncology nursing team, and a multidisciplinary tumour board. OPD consultations, second opinions, and post-operative follow-up are at Silver Leaf Clinic, 511 City Centre, Solapur Road, Hadapsar, Pune 411028. Call 88558 10010 to book at Silver Leaf Clinic.
Q193Does Dr. Gore provide second opinion consultations for cancer?
Yes — second opinion consultations are actively welcomed. Many patients told their cancer is inoperable at general hospitals are found to be resectable after specialist review. To arrange a second opinion: call 88558 10010 or WhatsApp 84118 08284. Bring all CT/MRI/PET-CT scans (on CD or WhatsApp), biopsy reports with IHC, blood investigations, operative notes if surgery has occurred, and chemotherapy or radiotherapy treatment summaries. Outstation patients can send scans via WhatsApp for preliminary review and arrange a video consultation before travelling to Pune. A second opinion does not delay treatment — it ensures the right treatment plan is in place from the start.
Q194Is teleconsultation (video consultation) available with Dr. Gore?
Yes. Video teleconsultation is available for outstation patients, international patients, and those seeking second opinions who cannot travel to Pune immediately. To arrange: WhatsApp 84118 08284 with your name, contact number, a brief description of the cancer, stage, and all available imaging and biopsy reports as image files or PDF. The team will confirm a consultation time. Video consultations cover: case review and resectability assessment, second opinion, pre-operative planning, and post-operative follow-up for established patients. Urgent oncological queries can also be addressed via WhatsApp. For in-person consultation at Silver Leaf Clinic, Hadapsar, Pune: call 88558 10010.
Q195What should I bring to my first cancer surgery consultation?
For the most productive first consultation with Dr. Gore, bring: CT scan, MRI, and PET-CT imaging on CD or USB (or share via WhatsApp before the appointment); biopsy and histopathology reports with full IHC panel; blood investigations — CBC, LFT, KFT, CEA, CA 19-9, or other relevant tumour markers; previous operative notes and pathology if prior surgery has occurred; chemotherapy or radiotherapy treatment summaries including drug names, cycles completed, and response assessment; any previous oncology consultation letters or MDT minutes; and a complete list of your current medications. The more complete the information provided, the more specific and clinically actionable the consultation will be.
Q196Does Dr. Gore accept insurance for cancer surgery at Sahyadri Manipal Hospital?
Yes. Sahyadri Manipal Hospital, Hadapsar accepts cashless insurance from most major TPA networks — Star Health, HDFC ERGO, New India Assurance, United India, National Insurance, Bajaj Allianz, and others. Pre-authorisation must be obtained from your TPA before admission for planned surgery. Ayushman Bharat (PMJAY) government scheme coverage is available for eligible patients — bring your Ayushman card to the consultation. MJPJAY (Maharashtra government scheme) is also accepted. The hospital billing department provides a detailed itemised cost estimate before surgery. For insurance queries contact Sahyadri Manipal Hospital billing directly after the OPD consultation at Silver Leaf Clinic.
Q197What is the OPD timing of Silver Leaf Clinic Pune?
Silver Leaf Clinic, 511 City Centre, Solapur Road, Hadapsar, Pune 411028. OPD hours: Monday to Saturday, 10:00 AM to 6:00 PM. Sunday: by prior appointment only. For appointment booking: call 88558 10010 or WhatsApp 84118 08284. Walk-in consultations may be available on the day if the schedule permits — calling ahead ensures an allocated appointment time and minimal waiting. Urgent oncological cases — new cancer diagnosis, acute obstruction, or clinical deterioration — are prioritised with same-day or next-day appointments whenever possible. Dr. Gore's team responds promptly to WhatsApp messages during clinic hours for clinical queries and report sharing.
Q198What is cancersurgeons.in?
cancersurgeons.in is the official comprehensive cancer surgery information and patient resource website of Dr. Vinod T. Gore — Senior Surgical Oncologist, Pune. It covers all major cancer surgery specialties including robotic surgery, HIPEC, electrochemotherapy, breast cancer surgery, GI and HPB surgery, head and neck cancer, gynaecological, urological, and thoracic cancer surgery. The Knowledge Hub section provides patient education through FAQ, Shorts, Video, Slideshow, and Blog content. Related specialist websites: bestroboticsurgeonpune.in for robotic surgery programme; bestbreastsurgeon.in for breast cancer surgery; bestthyroidsurgeon.in for thyroid surgery; cancerclinicpune.com for GI and colorectal cancer centre; and silverleafclinic.com for the clinic website.
Q199How to get a cancer second opinion in Pune from Dr. Gore?
To arrange a cancer surgery second opinion at Silver Leaf Clinic: Step 1 — call 88558 10010 or WhatsApp 84118 08284 to book; Step 2 — gather all records including CT/MRI/PET-CT on CD or WhatsApp, biopsy with IHC, blood tests, operative notes, and chemotherapy or radiotherapy summaries; Step 3 — attend consultation in person at Silver Leaf Clinic (Mon–Sat, 10AM–6PM) or arrange a video consultation for outstation patients; Step 4 — receive an honest independent assessment of diagnosis, resectability, and optimal treatment approach. The consultation does not commit you to treatment with Dr. Gore — a written clinical opinion can be provided for reference with your original treating team if requested.
Q200What makes Dr. Gore's cancer surgery programme distinctive in Pune?
Four characteristics distinguish Dr. Gore's programme at Sahyadri Manipal Hospital Pune. Subspecialty depth: 30+ years exclusively in surgical oncology, Tata Memorial Hospital trained, covering every cancer type from routine to highly complex multi-organ operations. Robotic leadership: FARIS Edinburgh certification, 300+ robotic procedures across all organ systems, ARIS Centre of Excellence — not limited to one cancer type. Innovation: Asia pioneer of ECT (2013); routine ICG fluorescence in all major operations; HIPEC available for peritoneal disease — all advanced techniques under one programme. Academic standing: Economic Times Trailblazer Leaders in Oncology 2025; Organising Secretary MOGCON, ICON, ASCO; FARIS training mentor — active in advancing oncosurgical standards in India. Call 88558 10010 to book.